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Abstract 
Targeted delivery of antibiotics via pH-responsive nano-formulations can combat the limitations 
of conventional dosage forms and reduce resistance development. Identification of new lipids for 
the preparation of nanocarriers is required for the development of pH-responsive systems. The 
aims of this study were to synthesize and characterize novel fatty acid based lipids [stearic acid 
derived solid lipid (SASL) and oleic acid derived liquid lipid (OALL)] and to explore their 
potential for the preparation of vancomycin pH-responsive nanostructured lipid carriers (VCM-
SAOA-NLCs). Biosafe lipids were synthesized and characterized using FTIR, 1H NMR, 13C 
NMR, and cytotoxicity. VCM-SAOA-NLCs were prepared using hot homogenization followed 
by ultrasonication technique and characterized in terms of size, polydispersity index (PDI), zeta 
potential (ZP), surface morphology, encapsulation efficiency (EE), in vitro drug release, in silico 
studies, in vitro and in vivo antibacterial activity in mice as well as bacterial cell viability studies. 
Biosafe lipids were successfully synthesized and characterized. Spherically shaped VCM-SAOA-
NLCs were prepared. VCM-SAOA-NLCs formulation size, PDI, and ZP were 225.9 ± 9.1 nm, 
0.258 ± 0.02 and -6.69 ± 1.1 mV respectively. EE was found to be 88.7 ± 13.12 %. In silico studies 
confirmed that the higher EE of VCM at a solid lipid to liquid lipid ratio of 2:1 (1603.991 
kcal/mol) than 1:1 (1367.44 kcal/mol) was due to the higher affinity of VCM with the solid lipid 
than the liquid lipid. In vitro drug release studies revealed that VCM-SAOA-NLCs had pH-
sensitive sustained drug release. In vitro antibacterial activity against methicillin-susceptible and 
resistant Staphylococcus aureus revealed that VCM-SAOA-NLCs had superior antibacterial 
activity compared to bare VCM against both bacterial strains at both pH conditions. Moreover, at 
pH 6 VCM-SAOA-NLCs activity was four times and two times better against SA and MRSA 
respectively than at pH 7.4. MRSA bacterial cell viability study showed enhanced uptake and 
antibacterial activity of VCM-SAOA-NLCs compared to bare VCM. Furthermore, the in vivo 
study revealed that MRSA CFU load in mice skin treated with VCM-SAOA-NLCs was 37-fold 
lower than bare VCM (P < 0.05).  
Therefore, this novel pH-responsive NLCs may serve as a promising nanocarrier for enhancing 
antibiotic delivery and activity. 
Keywords: nanostructured lipid carriers; pH-responsive; vancomycin; methicillin-resistant 
Staphylococcus aureus; antibacterial activity. 
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CHAPTER 1 
 INTRODUCTION 
 
1.1 Introduction  
This chapter outlines a brief background of the study including the status of infectious diseases, 
limitations of current antibiotic therapy and the growing threat of bacterial resistance. It further 
discusses the role of nanotechnology strategy based pH-responsive systems for combating the 
challenges encountered with antibiotic resistance. It further provides the aims, objectives, novelty, 
and significance of the study, and concludes with the structure and content of the thesis. 
1.2 Background  
Infectious diseases (ID) are considered one of the top ten leading causes of death globally and 
remain a major threat despite significant advances in research [1]. Emerging and re-emerging ID 
are associated with high mortality and morbidity rates and treatment costs, which affects the 
economic stability of societies [2]. The advent of antimicrobials in1940s revolutionized the 
treatment of ID and saved millions of lives. However, the current antibiotics dosage forms require 
optimal antimicrobial therapy administration of frequent high doses for a prolonged period to 
maintain sufficient concentration at infection sites [3], and to prevent therapy failure and infection 
recurrences [4, 5]. Exposure to high concentration of antibiotic is therefore associated with higher 
toxic and adverse effects, prolonged hospital residency, increased health care cost and poor patient 
compliance [6, 7]. 
 
These limitations, coupled with the overuse and misuse of antibiotics, have contributed to 
bacterial resistance development [8, 9]. The bacterial resistance crisis continues to spread, for 
multiple classes of antibiotics [10], and multidrug resistance (MDR) organisms are on the rise 
[11]. Concern has been heightened by methicillin-resistant Staphylococcus aureus (MRSA) 
bacteria emergence, which causes significant diseases, such as skin abscess, cellulitis, 
endocarditis and septic arthritis, and invasive bacteremia. The slow discovery and development 
of new antibiotics, the high costs of production and long approval times by regulatory bodies 
highlights the urgency to adopt new strategies to overcome the alarming increase of bacterial 
resistance [12] and limitations with conventional antibiotics. 
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Novel drug delivery systems, such as nanocarriers, have been investigated as a promising 
approach to address the limitations of antibiotic treatment and bacterial resistance [13-15]. Nano 
drug delivery systems (NDDS) are biocompatible small particles with large surface areas [16, 17] 
that hold several advantages including improving antibiotic solubility and biodistribution profiles 
[18-20], thus enhancing antibiotic bioavailability at the target sites [21, 22]. In addition, 
nanocarriers can enhance pharmaceutical stability [23] and release antibiotic at the site of 
infection in a controlled manner [24, 25], consequently reducing side and toxic effects [26] and 
improving patient compliance [27], which can lead to improving antibiotic efficacy and prevent 
the emergence of resistance. 
 
Several nanosystems have been reported for antibiotics delivery, including polymeric 
nanoparticles [28], liposomes [29], dendrimers [30], micelles [25] and solid lipid nanoparticles 
[31]. Of these nanosystems, nanostructured lipid carriers (NLCs) were proposed in the 1990s as 
a promising drug delivery system. NLCs are composed of solid lipids with a specified content of 
liquid lipids [32], this combination, offering several advantages, including biocompatibility, 
suitability for most routes of administration and feasible scale up production. In addition, NLCs 
improve drug loading capacity [33], protect loaded drugs against degradation, can incorporate 
both lipid and non-lipid soluble drugs [34] and control drug release [32], therefore, NLCs can be 
an efficient system for antibiotic delivery. 
 
Recently, nanotechnology research advances have focused on developing stimuli-responsive 
nanocarriers to potentiate the advantages of NDDS [35, 36]. Stimuli-responsive drug delivery 
systems are able to respond to a specific stimulus at a disease site, such as enzymes [37], pH [38], 
and temperature changes [39] to potentiate targeted drug release, thus enhancing drug 
accumulation and bioavailability at the site of action [36]. Certain disease conditions, such as 
cancer and infectious diseases, exhibit pH that differs from the physiological pH of 7.4 [40, 41]. 
This property can serve as a potential trigger for pH-responsive nanocarriers in targeting acidic 
pH conditions [42, 43]. pH-Responsive delivery systems have been efficiently explored for 
targeted delivery of anti-cancer drugs to tumor sites [44]. However, limited studies have been 
conducted on antibiotic delivery to the acidic infection site, which can greatly impact the 
treatment of ID through enhancing targeted antibiotic delivery, thereby minimizing systemic 
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antibiotic exposure, reducing adverse effects and overcoming conventional antibiotic dosage form 
limitations [28, 31, 38, 45, 46].  
 
Currently, vancomycin (VCM) is considered the last effective resort against infections caused by 
MRSA [47]. It is a tricyclic glycopeptide that binds D-alanyl-D-alanine moieties, thus preventing 
bacterial cell wall synthesis [48]. VCM has low bioavailability and is mainly administrated 
parenterally as it a large hydrophilic molecule besides its hydrophilicity [49]. However, the 
intravenous administration of VCM causes severe adverse effects, such as neutropenia, 
nephrotoxicity [50], ototoxicity and red man syndrome [51]. Additionally, the emergence and 
spread of VCM resistance is a growing health sector problem that is leading to increased mortality 
and morbidity rates [52], making it important to find strategies to improve VCM delivery and 
restore drug efficacy.  
 
Nanocarriers for VCM delivery have proven to be effective and can overcome the conventional 
dosage form limitations. The liposomal VCM formulation has prolonged circulation time and 
enhanced treatment efficiency [6, 53-55], while the VCM-SLNs formulation has improved 
entrapment efficiency and antimicrobial activity [12]. In addition, the lipid-polymer hybrid 
nanoparticles formulation has shown a sustained VCM release and antibacterial activity [23, 56], 
and Omolo et al reported on VCM-loaded polymersomes that potentially enhanced the anti-
MRSA activity [57]. However, to best of our knowledge, there is no literature reporting on the 
preparation of NLCs system for VCM delivery, despite their advantages.  
 
The development of pH-responsive nanocarriers requires identification of new materials such as 
polymers, lipids, polysaccharides, and peptides [58]. At acidic conditions, these materials achieve 
pH-responsive drug delivery via two mechanisms: і) protonation followed by pH-triggered 
conformational structural change and іі) hydrolysis of the acid labile bonds resulting in targeted 
drug release [58-61]. To the best of our knowledge, the only pH-responsive lipid for antibiotic 
delivery so far has been reported by Kalhapure et al in our group, who noted a pH-responsive acid 
cleavable lipid for a pH-responsive VCM loaded solid lipid nanoparticles preparation [31]. In 
addition, pH-responsive VCM polymeric nanoparticles that can protonate at acidic condition have 
been reported for enhancing VCM targeted delivery and antibacterial activity [28, 45]. No study 
to date has reported pH-responsive VCM loaded NLCs, highlighting the need to identify novel 
pH-responsive lipids for a pH-responsive VCM NLCs preparation. 
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In this study, we propose the synthesis of novel fatty acid based lipids [stearic acid derived solid 
lipid (SASL) and oleic acid derived liquid lipid (OALL)] to formulate pH-responsive NLCs. The 
solid lipid carboxylic acid group can form an ion-pair electrostatic interaction with the liquid lipid 
primary amino group. Consequently, at low pH, NLCs will protonate, resulting in NLCs surface 
charge switching from negative to positive, followed by ion-pair bond breakage, which can result 
in NLCs swelling and enhance drug release. Moreover, the positive charge of NLCs can promote 
binding to the anionic bacterial membrane, thus enhancing antimicrobial activity [12, 46, 57, 62, 
63], with no such lipids having been reported for any pH-responsive delivery of any drug class 
before.  
1.3 Problem statement 
Infectious diseases, particularly bacterial infections, have been recognized as a major cause of 
deaths globally due to the limitations of current antibiotic conventional dosage forms, including 
suboptimal concentrations at the target site of infection, poor pharmacokinetic profiles, higher 
frequent doses, potential side effects and poor patient adherence to treatment. These limitations 
have led to the development of an antibiotic resistance crisis and increased mortality and 
morbidity rates. The development of new antimicrobial agents is declining, highlighting the need 
to develop new strategies to improve current antibiotic therapy. The introduction of nano 
antibiotic delivery systems, primarily smart pH-responsive nano antibiotic delivery systems, can 
potentiate targeted antibiotic release, therefore enhancing antibiotic therapy. Despite the 
advantages of pH-responsive nano antibiotic delivery systems, to best of our knowledge, no study 
has been conducted on pH-responsive NLCs for antibiotic delivery to date.  
1.4 Hypothesis or research question  
We hypothesized that the synthesis of novel pH-responsive fatty acids based lipids to formulate 
VCM loaded NLCs can enhance its targeted delivery. It can also increase its localization at acidic 
bacterial infection site and enhance its antibacterial efficacy. This can lead to the protection of the 
antibiotic during systemic circulation and it can lead to the reduction of the dosage required for 
optimal therapy. Subsequently, it reduces the dose dependent-adverse effects and improves 
patient’s compliance.  
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1.5 Aims and Objectives 
The aim of this study was to explore the potential of novel fatty acids based lipids to formulate 
VCM loaded NLCs to enhance its antibacterial efficacy. 
In order to achieve this aim, the objectives of the study were: 
1. To synthesize pH-responsive novel fatty acid based lipids [stearic acid derived solid lipid 
(SASL) and oleic acid derived liquid lipid (OALL)]. 
2. To characterize SASL and OALL synthesized lipid using FT-IR, 1H NMR and C13 NMR 
and cytotoxicity studies. 
3. To explore the potential of SASL and OALL novel lipids to prepare vancomycin loaded 
pH-responsive nanostructured lipid carriers from (VCM-SAOA-NLCs). 
4. To optimize and characterize VCM-SAOA-NLCs in terms of size, polydispersity index, 
zeta potential, pH responsiveness, morphology, entrapment efficiency, in vitro drug 
release, in vitro and in vivo antibacterial activity. 
5. To undertake in silico studies to understand the interactions between VCM and lipids 
carriers (SASL and OALL) as well as the effect of lipid ratio on entrapment efficiency 
1.5 Novelty of the study 
The research conducted in this study is novel for the following reasons: 
• In this study, pH-responsive NLCs were formulated from a newly designed and 
synthesized solid lipid (SASL) and liquid lipid (OALL). These lipids are novel and have 
not been reported for any pH-responsive nano-formulations. 
• Although pH-responsive solid lipid nanoparticles [31] and polymeric nanoparticles [28, 
45] have been reported for enhancing VCM antibacterial efficiency at acidic infection 
sites, no study has reported pH-responsive NLCs loaded with VCM. This is the first study 
on pH-responsive NLCs for targeting VCM release and enhancing antibacterial activity 
at acidic infection sites. 
• While several nano delivery systems have been developed for VCM, such as 
polymersomes [57], liposomes [53, 64], dendrimers [23, 65], lipid-polymer hybrid 
nanoparticles [56], solid lipid nanoparticles [12] and nanoplexes [66], to best of our 
knowledge, this is the first study that reports a VCM-loaded NLC formulation. 
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1.6 Significance of the study 
This reported pH-responsive NLCs carrier presents a novel and promising approach for targeting 
poorly soluble antibiotics into acidic infection sites, therefore enhancing drug activity and 
preventing resistance development. The potential significance of the formulation explored in this 
study are: 
 
New Pharmaceutical Products 
This study proposes novel pH-responsive lipids as pharmaceutical materials and a new pH-
responsive NLCs formulation as a medicine. This novel pharmaceutical material and medicine 
can represent a basic platform for the pharmaceutical industry to develop new pH-responsive 
delivery systems that could be superior to other conventional dosage forms. 
 
Improved patient therapy and disease treatment 
This novel pH-responsive nanocarrier can improve bacterial infection treatment by protecting 
the antibiotics during systemic circulation, improve targeted and sustained antibiotic release, 
and enhance antibiotic localization and bioavailability at the acidic infection sites. This can 
contribute to improving the antibacterial activity, and reduce dosing frequency and adverse 
effects. This can lead to improving patient compliance, enhancing antibacterial therapy and 
combating antimicrobial resistance threats. 
Stimulation of new research 
This study can provide new potential research directions for: 
• The synthesis and characterization of pH-responsive lipids and other materials for their 
potential applications in pH-responsive nanosystems formulation for various drug 
classes.  
• Further optimization of NLCs formulation  and process variables to be suitable for 
eventual patients use. 
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1.7 overview of the Dissertation 
The research is presented in the following chapters: 
 
CHAPTER 1. Introduction:  
This chapter provides a brief background of the study including the status of infectious diseases, 
limitations of current antibiotic therapy and the growing threat of bacterial resistance. It further 
discusses the role of nanotechnology strategy based pH-responsive systems for combating the 
challenges encountered with antibiotic resistance. Additionally, it provides the aims, objectives, 
novelty, and significance of the study, and concludes with the structure and content of the thesis. 
 
CHAPTER 2. Literature Review:  
This chapter outlines an overview of the current status of infectious diseases and antibiotic therapy 
limitations which have led to the development of bacterial resistance. It outlines the use of pH-
responsive nano drug delivery as a strategy to influence the treatment of infectious diseases. It 
also describes nanostructured lipid carrier features, preparation, and characterization methods and 
concludes with an overview of vancomycin as a model drug. 
 
CHAPTER 3. Submitted manuscript: 
This chapter is a first author article that was submitted to an international ISI journal i.e. European 
Journal of Pharmaceutics and Biopharmaceutics (Impact factor of 4.389). The chapter is presented 
in the required format of the journal, it describes the formulation of novel vancomycin pH-
responsive loaded nanostructured lipid carriers that showed enhanced antibacterial activity.  
 
CHAPTER 4. Conclusion:  
This chapter describes the conclusions reached in achieving the study aim, outlines the 
significance of the findings and makes recommendations for further research into antibiotic-
loaded pH-responsive nanostructured lipid carriers.  
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CHAPTER 2. LITERATURE REVIEW 
 
2.1 introduction 
This chapter provides an overview of the current status of infectious diseases and antibiotic 
therapy limitations that have led to the development of bacterial resistance. It outlines the use of 
pH-responsive nano drug delivery as a strategy to influence the treatment of infectious diseases. 
It also describes nanostructured lipid carrier features, and preparation and characterization 
methods, and concludes with an overview of vancomycin as a model drug. 
2.2 Current infectious diseases burden and antibiotic therapy limitations 
Infectious diseases (ID) are a major public health problem globally, despite the success of 
antimicrobial therapy [67-71]. ID epidemiology is affected by several factors, such as changes in 
human behavior and ecology, economic growth, industrial development, human migration, trade 
and genomics of bacterial pathogens [72]. The ongoing crisis of ID is associated with high 
morbidity and mortality rates in developing and developed countries (Fig. 1) [2], with diarrhea, 
tuberculosis and lower respiratory tract infections being among the top ten leading causes of death 
[73]. In 2015, bacterial infections were the main cause of death among children under age of five 
in Africa [74], whereas in South Africa, tuberculosis infection accounted for 12% of deaths in 
2010 and remained the leading cause of death until 2015 (Fig. 2) [75].  
 
Fig. 1. Leading causes of death in developing and developed countries [73]. 
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Fig. 2. Cause of death in South Africa [76]. 
 
Since the discovery of antibiotics in the 1940s, ID therapy changed dramatically, with their 
introduction significantly contributing to infection prevention, treatment, and control [77, 78]. 
Antibiotics have different classes according to their mechanism of actions, such as cell wall 
synthesis inhibitors, protein synthesis inhibitors, cell membrane disrupters, nucleic acid synthesis 
inhibitors and antimetabolites (Fig. 3) [79]. Antibiotics are available in  number of dosage forms 
including tablets, capsules [80], suspensions [81], injections [82], creams and ointments [83, 84].  
 
Optimum antibiotic therapy should provide an effective concentration at the infection site with 
low systemic adverse effects. However, these current conventional antibiotic dosage forms are 
associated with suboptimal antibiotic concentration at the infection site and poor stability. In 
addition, poor pharmacokinetic properties, such as insufficient absorption, rapid metabolism, and 
excretion from the body, lead to reduced tissue penetration and low bioavailability at the infection 
site [4, 85, 86]. Subsequently, high frequent antibiotic doses are required to achieve sustained 
therapeutic concentration, these often being associated with increased systemic adverse effects, 
high costs and poor patient adherence to therapy [6]. The conventional antibiotics dosage form 
limitations, together with irrational antibiotic use, are the key issues in ID therapy failure, 
infection re-emergence and the development of bacterial resistance (Fig. 4) [5].  
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Fig. 3. History of antimicrobial agent development and resistance by microorganisms [27]. 
 
Bacteria can acquire antibiotic resistance intrinsically or by horizontal gene transfer [87]. The 
main resistance mechanisms include minimizing antibiotic uptake [88], genetic modification of 
the antibiotic target site [89], activation of antibiotic efflux pump [90] and antibiotic enzymatic 
inactivation (Fig. 4) [87, 91]. Bacteria strains that are resistant to multiple classes of antibiotics 
represent a major persistent health challenge, with multidrug resistance (MDR) bacterial infection 
being untreatable and associated with ineffective, more toxic and expensive antibiotic therapy 
[10, 11, 92]. 
 
 
 
Fig. 4. Commonly used antibiotics mechanism of action [79].  
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Among the MDR bacteria, methicillin-resistant Staphylococcus aureus (MRSA) was identified in 
1961 [93], the causative organism causing serious infection such as skin and soft tissue infection, 
endocarditis and bacteremia, which are associated with raised morbidity and mortality rates, 
increased therapy cost and prolonged hospital stay [94-97].  
 
The antibiotic resistance crisis requires the intervention of health sectors experts, policy makers, 
health authorities, pharmaceutical companies and community members in order to undertake 
collaborative efforts and approaches to combat bacterial resistance [15, 98]. While bacterial 
resistance is growing, the development rate of new antimicrobials against MDR organisms is 
declining [99],  due to high production costs, long drug approval processes period, poor return on 
investment compared to other drug classes and regulatory body barriers (Fig. 5) [12, 72, 94, 100]. 
Thus, new strategies have been investigated to improve conventional antibiotic dosage forms 
delivery and restore efficacy [14, 15] such as individualizing antibiotic therapy [101], antibiotic 
therapeutic drug monitoring [102, 103] and delivering antibiotics in controlled and targeted 
delivery [104, 105]. 
 
 
Fig. 5. Declining number of new antibiotics [9]. 
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2.3 Nanoengineered antibiotic delivery systems 
Nanotechnology is the science that engineers designs and characterizes nanometer-scale materials 
for various applications [106], with nanoparticles having a small particle size with a large surface 
area. In addition, nanoparticle surface can be modified and functionalized for their potential 
applications, which results in nano drug delivery systems (NDDS) being a promising carrier for 
enhancing antibiotics delivery and improving efficacy at the site of infection (Fig. 6). Several 
NDDS have being investigated for encapsulating various classes of antibiotic against a wide range 
of bacteria (Table 1), such as: polymeric nanoparticles [107], liposomes [29], dendrimers [30], 
micelles [25] and solid lipid nanoparticles [4, 12], nanoemulsions [108], carbon nanotubes [109], 
polymersomes [57] and nanostructured lipid carriers [110, 111]. These nanosystems have been 
widely applied for different routes of antibiotics administration, such as: oral [112], parenteral 
[113], topical [114], inhalation [114] and transdermal [115].  
 
NDDS have several advantages over the conventional antibiotic dosage forms, such as: improving 
antibiotic solubility and bio-distribution profiles [18-20], enhancing tissue penetration and 
bioavailability at infection sites [21, 22], enhancing antibiotic pharmaceutical stability [23], 
targeting and controlling antibiotic release at infection site [24, 116] improving antibiotic 
localization at intracellular sites [117, 118] and achieving synergistic effects via co-delivery of 
antibiotic and antimicrobials [119-122]. In addition, NDDS can potentiate antibacterial therapy 
due to its lower frequent dosing and systemic side effects [26], which promotes patient 
compliance [27]. Therefore, NDDS can overcome conventional antibiotics dosage forms 
limitations, and offer a promising approach that can improve antibiotic therapy and consequently 
prevent bacterial resistance development [14, 27]. 
 
 
Fig. 6.   Examples of nano-delivery systems reported for antibiotics 
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Table 1. Examples of nanosystems reported for antibiotics. 
 
Nanosystem Encapsulated 
antibiotic 
Targeted bacteria Mechanism for improved 
antibiotic efficacy  
Reference 
Polymeric 
nanoparticles 
Levofloxacin Escherichia coli - Sustained drug release. 
- Enhanced the biofilm 
inhibitory activity. 
[123] 
Liposomes  Polymyxin B Pseudomonas 
aeruginosa 
- Sustained drug release. 
- Enhanced lung delivery. 
[124] 
Dendrimers  Ciprofloxacin Staphylococcus 
aureus and 
Escherichia coli 
- Co-administration of 
dendrimers reduced 
the effective required dose of 
the drug.  
- Synergistic antibacterial 
activity. 
[125] 
Micelles  Ciprofloxacin Bacillus subtilius 
and Escherichia 
coli 
- Enhanced drug uptake 
across the Blood-Brain 
Barrier. 
[116] 
Solid lipid 
nanoparticles 
Meropenem Escherichia coli - Controlled release and 
enhanced antibacterial 
activity. 
[4] 
Nanoemulsions Amoxicillin Helicobacter 
pylori 
- Controlled drug release. 
- Enhanced drug localization 
at the site of infection.  
[126] 
Polymersomes Vancomycin  Staphylococcus 
aureus and 
methicillin-
resistant 
Staphylococcus 
aureus 
- Sustained drug release and 
in vitro and in vivo 
antibacterial activity 
[57] 
 
2.4 Nanostructured lipid carriers  
Nanostructured lipid carriers (NLCs) were developed in the 1990s as the second generation of 
solid lipid nanoparticles (SLNs), and are composed of a matrix of biodegradable/biocompatible 
solid and liquid lipids coated with surfactant (Fig. 7) [127]. NLCs lipid matrix is less ordered due 
to the presence of the liquid lipid, which results in the drug loading capacity being superior to 
SLNs [128]. In addition, NLCs have several advantages, including biocompatibility, suitability 
for drug delivery via different routes of administration [33], high storage stability [129], simple 
scale up production [32]. Also, NLCs can protect the loaded drug against degradation [34], 
incorporate lipophilic and hydrophilic drugs [34, 130], control drug release [32, 131] and enhance 
drug bioavailability [132]. These advantages make NLCs an efficient nanocarrier for antibiotic 
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delivery in order to improve ID therapy via targeted antibiotic release, enhance antibiotic 
bioavailability at infection site and prevent bacterial resistance. 
 
Fig. 7.   Nanostructured lipid carriers structure [133]. 
 
2.4.1 NLCs composition 
NLCs are mainly composed of biodegradable/biocompatible solid and liquid lipids and 
emulsifier. The most common solid lipid used for NLCs preparation are cetyl palmitate, glyceryl 
monostearate, stearic acid, glyceryl palmitostearate, cholesterol, glycerol behenate and glyceryl 
tripalmitate.  The most commonly used liquid lipids are oleic acid, miglyol 812, castor oil, and 
medium chain triglycerides. Poloxamer 188/407, polysorbate 80/40/20 and phosphatidylcholines 
are often employed as the emulsifier [7, 134, 135]. 
 
2.4.2 Types of NLCs  
NLCs are classified based on the structure, lipid composition, and ratios into 3 types (Fig. 8) 
1) Imperfect type: These NLCs are composed of different ratios of solid and liquid lipids 
matrix that have imperfect crystalline lipid order, which results in them having high drug 
loading capacity due to the imperfect lipid matrix. 
2) Amorphous type: This type of NLCs is produced by mixing the solid lipid with specific 
liquid lipids, such as hydroxy octacosanylhydroxystearate, isopropyl myristate and 
medium chain triglycerides that can form amorphous lipid matrix. This type has high 
storage amorphstability due to the o lipid matrix us.  
3) Multiple type: In this type, a higher amount of liquid lipid is added to the lipid phase in 
order to enhance the hydrophobic drug solubilization [92, 136]. 
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Fig. 8. Types of Nanostructured lipid carriers [136]. 
 
2.4.3 Methods applied for NLCs production  
Several methods have been applied to produce NLCs, including high pressure homogenization 
(HPH) [33], solvent emulsification-evaporation [137], solvent diffusion method [138], solvent 
injection [139], phase inversion [140], emulsification sonication and membrane contractor 
techniques [34]. HPH is the most commonly used method for NLCs preparation as it has several 
advantages, such as the ability to produce small particle sizes, simple scale up production and 
short production time compared to the other methods [141, 142]. 
 
HPH can be done at different temperature ranges, the hot method being done at a temperature 
degree above lipid melting point, the drug is mixed with lipid melt, then the drug-containing lipid 
is dispersed in the hot aqueous surfactants phase. Subsequently, both phases are homogenized 
using high shear mixing device resulting in emulsion formation, which is subjected to cooling to 
obtain NLCs (Fig. 9 A) [135, 143, 144]. The cold HPH is done by dissolving the drug in the lipid 
melt, followed by solidifying it using dry ice or liquid nitrogen. Subsequently, the drug-lipid 
mixture is milled and dispersed in a cold surfactant solution (Fig. 9 B) [136, 145]. The hot HPH 
technique can result in smaller particle size than the cold HPH due to lipid viscosity reduction at 
high temperature. However, increasing the homogenization temperature can accelerate the drug 
and lipid degradation rate [135, 136]. 
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Fig. 9. Homogenization technique. A) Hot homogenization technique B) Cold homogenization 
technique [146]. 
 
2.4.4 NLCs characterization  
Various methods are used for NLCs characterization in order to explore their potential application 
and quality evaluation. NLCs are characterized in terms of particle size, particle size distribution, 
surface charge, morphology and other parameters, these being critical indicators of NLCs quality, 
stability, and biological kinetics profiles. Moreover, these parameters can significantly influence 
biological membrane penetration, distribution, excretion and drug release [131]. 
 
Particle size and size distribution  
Analytical instruments based on dynamic light scattering (DLS), scanning electron microscopy 
(SEM) and transmission electron microscopy (TEM) techniques are commonly used to determine 
the particle size. The DLS technique is the most frequently used for particle size and size 
distribution (expressed as the polydispersity index (PDI)) determination as it is practical and 
simple [131, 142, 147, 148]. 
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Surface charge 
Nanoparticles surface charge, expressed as zeta potential (ZP), is a critical measure for NLCs 
stability assessment during storage. High positive or negative ZP values indicate high electrostatic 
repulsion, thus, NLCs particles avoid aggregation and better system stability is maintained. 
Analytical instruments based on the DLS technique is used for ZP measurement [131, 142, 148, 
149]. 
 
Morphology 
SEM and TEM techniques are additionally used for NLCs shape and morphology studies [150, 
151].  
 
Entrapment efficiency (EE) 
Drug entrapment efficiency (EE) is the amount of drug that has been entrapped in the nanoparticle 
lipid matrix, hence lipophilic drugs have higher EE than hydrophilic drugs. The free 
(unentrapped) drug is separated from the NLCs using ultra-centrifugation, ultra-filtration and gel 
permeation methods, after which the free drug quantity is analyzed using the HPLC or UV method 
[32, 137, 152]. 
 
Thermal profiles 
Analytical instruments based on X-ray spectroscopy and differential scanning calorimetry 
technique are widely used to investigate NLCs crystallization state and thermal behavior [136]. 
 
In vitro drug release 
Drug release studies are commonly carried out using dynamic dialysis bag method to investigate 
the release behavior of drug loaded NLCs. The samples are analyzed for the drug content using 
an analytical method, such as HPLC or UV [153]. Several factors can influence NLCs drug 
releases, such as NLCs particles size, surface area, and lipid matrix viscosity. Additional NLC 
characterization studies can be performed depending on the application of NLCs. 
 
2.4.5 NLCs for antibiotic delivery 
Despite the successful outcomes of NLCs application for several drug classes delivery via 
different routes of administration such as oral [130, 131, 154], topical [155, 156], parenteral [153, 
157] and pulmonary [158, 159], few studies have been conducted on NLCs antibiotics delivery. 
Moreno-Sastre et al reporting tobramycin loaded NLCs against Pseudomonas aeruginosa 
infections, the results showing improved EE, sustained release beside increased pulmonary 
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distribution of the drug [111]. Similar results were reported by Pastor et al., where NLCs enhanced 
sodium colistimethate target release and antibacterial activity against Pseudomonas aeruginosa 
infection [160]. Rifampicin loaded NLCs showed improved pharmacokinetic profiles that 
enhanced the pulmonary targeted delivery [161].  
 
However, there is a need for a nano antibiotic carrier that efficiently protects and stabilize the 
antibiotic during systemic circulation, and enhances targeted antibiotic release and localization at 
infection sites. Thus, researchers have recently explored “smart” nanosystems to further improve 
the first generation of nano antibiotic delivery systems [7, 35, 162, 163]. 
2.5 pH-Responsive drug delivery system 
Recent research advances focus on developing nanocarriers that release the drug in response to 
various stimuli, such as pH, enzymes, ultrasound, electric field, magnetic field and temperature 
[37, 39, 164-166]. Stimuli-responsive drug delivery strategy can improve drug protection against 
degradation over systemic circulation [44], target drug release, increase intracellular uptake and 
drug accumulation at the site of action [36]. This can lead to enhanced drug stability, 
bioavailability and therapeutic effectiveness [35]. Hence, “smart” nanosystems can be more 
promising drug delivery carriers than the conventional NDDS. 
 
Current investigations of pH-responsive drug delivery system that can target and release the drug 
in response to a pH-change stimulus have received much attention [167]. Certain body 
compartments, such as gastrointestinal tract and disease pathophysiological conditions (e.g. 
tumors and infections) exhibit pH different from the physiological pH of 7.4. This property can 
potentially trigger the design of pH-responsive nanosystems for targeted drug release [35, 40, 41]. 
Table 2 summarize studies reported on pH-responsive drug delivery nanosystems. The 
development of pH-responsive nanocarriers requires the identification of new materials, with the 
literature reporting various pH-responsive materials, such as polymers, lipids, polysaccharides, 
and peptides [58]. 
 
2.5.1 pH-responsiveness mechanisms 
At acidic conditions, these materials achieve pH-responsiveness via two mechanisms: 
1) Protonation: pH-Responsive materials are designed to have ionizable groups that remain 
unprotonated, while in acidic pH these groups undergo protonation and a surface charge 
reversal, resulting in structural and conformational changes followed by drug release.  
Literature review   Chapter 2 
26 
 
2) Acid-labile bonds hydrolysis :pH-responsive materials can form an acid-labile bond with 
a drug that undergoes hydrolysis at the acidic condition, resulting in drug release [58-61]. 
 
2.5.2 pH-Responsive nanocarriers application 
One of the most promising applications of pH-responsive nanocarriers is pH-responsive tumor-
targeted drug delivery, which can protect cytotoxic drug at the physiologic pH of 7.4, target the 
drug release, and enhance drug localization and uptake at the acidic tumor site. They can, 
therefore, enhance the cytotoxic activity and prevent resistance development [38, 42, 43]. 
Additionally, pH-sensitive nanocarriers can impact Helicobacter pylori therapy by improving 
drug protection at the acidic gastric site, enhancing targeted release and uptake at infection  
site[168-170].  
 
Some bacterial infections are acidic, as bacteria produce acetic acid and lactic acid under 
anaerobic conditions. Therefore, the pH-responsive strategy can be applied to enhance antibiotic 
target delivery, reduce healthy site exposure to antibiotic, target and control antibiotic release and 
increase antibiotic localization at the acidic infection site, which can enhance antibacterial activity 
and prevent bacterial resistance development [28]. 
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Table 2.  Examples of pH-responsive nano delivery systems 
 
Drug pH-responsive 
nanosystem 
Main findings Reference 
Amoxicillin Polymeric 
nanoparticles 
Drug protection against gastric acid degradation. 
Enhanced antibacterial activity against Helicobacter 
pylori in the infected gastric mucosa. 
[168] 
Heparin Polymeric 
nanoparticles 
Enhanced drug interaction with Helicobacter pylori 
infection site thereby increasing gastric mucosal cells 
regeneration. 
[169] 
Tenofovir Polymeric 
nanoparticles 
Enhanced intravaginal drug delivery for HIV 
transmission prevention. 
[40] 
Cisplatin Polymeric 
nanoparticles 
Improved targeted drug delivery at the acidic lysosome 
environment in cancer cells led to improved drug 
efficacy. 
[42] 
Paclitaxel Polymeric 
nanoparticles 
Improved drug loading capacity and targeted drug 
release at the acidic tumor site. 
[171] 
Doxorubicin Polymeric 
Nanoparticles 
Improved drug intracellular bioavailability and 
enhanced its cytotoxic activity. 
[172] 
Vancomycin  SLNs Enhanced encapsulation efficiency and release at 
acidic pH. 
In vitro and in vivo studies showed better anti-MRSA 
activity. 
[46] 
Curcumin SLNs Sustained drug release with higher stability and 
bioavailability at acidic conditions. 
[173] 
Doxorubicin SLNs Superior proliferative inhibition of multidrug-resistant 
cancer cells. 
[62] 
Vancomycin Polymeric 
Nanoparticles 
Stronger binding to the bacterial surface in acidic 
media compared to the basic one, led to better 
antimicrobial efficacy against SA compared to the free 
drug. 
[28] 
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2.6 Vancomycin as a model drug for antibiotic therapy 
Vancomycin (VCM) is a tricyclic glycopeptide bactericidal antibiotic (Fig. 10), and acts by 
making a complex with the D-alanyl-D-alanine moieties, thereby inhibiting the peptidoglycan 
synthetase enzyme, and subsequently preventing peptidoglycan formation and  cell wall 
biosynthesis [48]. 
 
 
Fig. 10. VCM structure [12].  
 
2.6.1 VCM activity 
VCM is administered orally to treat pseudomembranous colitis infections, which is caused by 
Clostridium difficile bacteria and is administrated parenterally for MRSA infections. It has been 
considered as a standard effective resort for treatment and prophylaxis of the life-threatening 
Gram-positive bacterial infections, such as skin infections, bacteremia, and endocarditis that are 
unresponsive to other antibiotic classes [47, 49, 174] 
 
2.6.2 VCM adverse effects 
Parenteral administration of VCM is associated with severe adverse effects, such as neutropenia, 
nephrotoxicity [50], ototoxicity and most commonly red man syndrome [51, 175]. 
 
2.6.3 VCM nano delivery systems 
VCM is a hydrophilic large molecule, thus it has low absorption, bioavailability and tissue 
penetration [49]. In addition, the emergence and spread of VCM resistance is a growing health 
sector problem causing VCM treatment failure and increased minimum inhibitory concentration 
[52]. VCM nano delivery systems have proven to be very effective compared to VCM 
conventional dosage forms. Liposomal VCM formulation had prolonged circulation time and 
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enhanced antibacterial efficiency [6, 53, 55], while SLNs were a suitable carrier to improve VCM 
entrapment efficiency and antimicrobial activity [12]. Lipid polymer hybrid nanoparticles 
formulation showed a sustained VCM release and antibacterial activity [56]. Omolo et al reported 
VCM-loaded polymersomes that potentially enhanced its anti-MRSA activity [57]. 
 
2.6.4 VCM pH-Responsive nanosystems  
Smart nano delivery systems have been applied for enhanced targeted VCM delivery [28, 31, 45, 
176], with Kalhapure et al having reported pH-responsive acid cleavable lipid for pH-responsive 
vancomycin loaded SLNs preparation, their results showing enhanced antibacterial activity 
against methicillin-susceptible and resistant Staphylococcus aureus [31]. pH-responsive 
vancomycin polymeric nanoparticles have also been reported for enhancing drug targeted 
delivery and activity [28, 45]. Thus, pH-responsive nanosystems for VCM targeted delivery can 
contribute to enhancing VCM efficacy, overcome VCM conventional dosage forms limitations, 
and combat bacterial infections and bacterial resistance. advHowever, despite the unique a ntage, 
NLCsof ,  there is no literature data reported on the preparation of pH-responsive NLCs system 
for VCM delivery yet.   
2.7 Conclusion  
The chapter highlighted the literature findings of the current state of infectious diseases, lack of 
effective antibiotic therapy and the emergence of antibiotic resistance. It also outlined the role of 
nano drug delivery systems, mainly pH-responsive nanosystems, in overcoming antibiotic therapy 
limitations. Although extensive research has been conducted on NLCs potential applications, no 
study has been reported on pH-responsive NLCs for antibiotic delivery yet, such system possibly 
being the new “magic bullets” to restore the efficacy of the antibiotic and prevent the post-
antibiotic era evolution. 
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Abstract 
The aim of the present study was to synthesize and characterize novel fatty acid based 
lipids [stearic acid derived solid lipid (SASL) and oleic acid derived liquid lipid (OALL)] 
and explore their potential for preparing vancomycin pH-responsive nanostructured lipid 
carriers (VCM-SAOA-NLCs). Biosafe SASL and OALL were successfully synthesized 
and VCM-SAOA-NLCs were prepared using the hot homogenization technique. VCM-
SAOA-NLCs size, polydispersity index, zeta potential and encapsulation efficiency were 
found to be 225.9 ± 9.1 nm, 0.258 ± 0.02, -6.69 ± 1.1 mV and 88.7 ± 13.12 % respectively. 
In silico studies showed higher VCM encapsulation efficiency at 2:1 than 1:1 solid lipid 
to liquid lipid ratio. In vitro drug release studies revealed that VCM-SAOA-NLCs had 
pH-sensitive sustained drug release. In vitro antibacterial activity against methicillin-
susceptible and resistant Staphylococcus aureus revealed that VCM-SAOA-NLCs had 
superior antibacterial activity compared to bare VCM against both bacterial strains at both 
pH conditions. MRSA bacterial cell viability study showed enhanced uptake and 
antibacterial activity. Furthermore, the in vivo study revealed that MRSA CFU load in 
mice skin treated with VCM-SAOA-NLCs was 37-fold lower than bare VCM (P < 0.05). 
Therefore, this novel pH-responsive NLCs may serve as a promising nanocarrier for 
enhancing antibiotic delivery and activity. 
 
Keywords: pH-responsive; nanostructured lipid carriers; vancomycin; methicillin-
resistant Staphylococcus aureus;  fatty acid   
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1. Introduction 
The golden era of antibiotic discovery was followed by the emergence of drug resistance, 
which has become a considerable health threat globally and is leading to higher medical 
costs for individuals and healthcare sectors [177-179]. Infectious organisms have 
developed resistance to multiple classes of antibiotics [180]. Of concern are community 
and hospital-acquired methicillin-resistant Staphylococcus aureus (MRSA) infections, 
which pose a major therapeutic challenge, and are associated with raised risks of 
treatment failure and mortality rates [181-183]. Although vancomycin (VCM) has been 
the most effective antibiotic against MRSA [184], there are several reports of resistance 
and therapy failure, highlighting the need for new strategies to enhance its activity and to 
prevent the spread of resistance [174, 185, 186]. 
Current conventional antibiotics dosage forms have several disadvantages, including 
insufficient therapeutic concentration at infection sites [187], poor intracellular uptake, 
and exposure to noninfectious/healthy sites [188]. In addition, effective therapy for 
infectious disease is achieved via high antibiotic doses and frequent administration [179]. 
This leads to increased incidence of adverse drug reactions, toxicity and poor patient’s 
adherence [189, 190], which contribute significantly to resistance development [191]. 
Novel drug delivery systems for antibiotics delivery is therefore explored as a strategy to 
overcome limitations with conventional antibiotics dosage forms [14]. 
Nano drug delivery systems (NDDS) are a promising approach to enhance antibiotics 
delivery due to their small particle size, large surface area and biocompatibility [192]. 
These unique properties offer several advantages, including increased therapeutic 
concentration at the infection site [193], and sustained and targeted release of antibiotics 
[185], therefore enhancing bioavailability [179] and reducing systemic exposure of 
antibiotics [194, 195]. These systems enhance the efficacy of conventional antibiotics, 
reduce their side effects and can overcome resistance [31, 196]. 
Various types of nano-carriers are currently used to deliver antimicrobial drugs, including 
polymeric nanoparticles [28, 123, 197], liposomes [29, 193], dendrimers [23], 
polymersomes [57] micelles [116] and solid lipid nanoparticles (SLNs) [198, 199]. 
Nanostructured lipid carriers (NLCs) have attracted major attention recently as a drug 
delivery system. NLCs are composed of liquid and solid lipids, this combination offers 
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prime advantages of improved drug loading capacity [200, 201], incorporating both 
hydrophilic and hydrophobic drugs, enabling simple large-scale production, 
biocompatibility [154, 202] and enhanced storage stability [147, 203]. Moreover, NLCs 
protect the loaded drug against degradation, enable improved drug bioavailability [149, 
159] and achieved drug release in a controlled and targeted manner [204, 205]. These 
features have made NLCs highly competent in comparison to other nanoparticle carriers 
[206], and can, therefore, be a promising nanocarrier for antibiotic delivery. 
More recently, a new approach to enhance therapeutic outcomes with NDDS has focused 
on the development of nanosystems that respond to stimuli, such as light, pH, electric 
fields, magnetic field and temperature changes [39, 207]. Stimuli-responsive nanosystems 
offer enhanced drug protection against degradation during systemic circulation and 
increase the release of the loaded drug at the target site in response to the stimuli [44]. 
One of the most promising smart nanocarriers is pH-responsive nanosystem, which 
ideally releases the drug in response to pH changes at its target site [44, 208]. Several 
diseases, such as cancer, gastric and duodenal ulcers, besides some bacterial infections, 
exhibit acidic pathophysiological states that can provide a suitable stimulus for pH-
responsive systems [38, 167, 209, 210]. These systems for antibiotic delivery can be used 
to decrease drug loss from nanoparticles prior to reaching the infection sites [31, 38, 44], 
increase drug release at the infection site and promote interaction with the bacteria [28].  
Although numerous studies have been reported for pH-responsive systems in tumor 
targeting, there have been very few on developing pH-responsive nanoparticles for 
antibiotic delivery [171, 211]. At low oxygen concentration, certain bacteria initiate 
anaerobic fermentation that produces lactic and acetic acids. This acidic infection site 
serves as an ideal platform for pH-responsive nanocarriers to possess acid triggered 
targeted antibiotic release [28]. Developing nanoparticles with surface charge switching 
property at acidic media can enhance cationic fusion with the anionic bacterial cell wall 
and therefore facilitate the availability of higher antibiotic concentration at the bacterial 
site [31]. Thus, pH-responsive targeted delivery systems can enhance antibiotic delivery, 
minimize systemic antibiotic exposure, reduce adverse effects and help to overcome 
antibiotic resistance mechanisms [28, 31, 45].  
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Despite the advantages of NLCs, no study has reported pH-responsive NLCs for 
antibiotic delivery, highlighting the need to identify novel lipids to prepare them. We 
hypothesize that pH responsiveness can be accomplished via NLCs via a combination of 
free fatty acid derived solid lipid with a carboxylic acid group and a liquid lipid with a 
primary amino group that can form an ion pair by electrostatic interaction. These 
interactions are mainly influenced by the pH-dependent ionization property of both acid 
and base in aqueous solution. The self-assembling properties of NLCs formed by this 
combination of the solid and liquid lipid can be pH sensitive. In addition, free fatty acid 
lipids increase bacterial membrane permeability and hold antimicrobial activity against 
wide ranges of bacteria including MRSA [12, 31, 57, 62, 63]. These properties could 
represent a potential solution to overcome bacterial resistance via engineering the free 
fatty acids lipid nanocarriers to develop pH-sensitive NLCs system that can enhance 
antibacterial activity [28, 31, 45]. No such lipids have been reported for any class of drug.  
The aim of this study was, therefore, to synthesize and characterize novel fatty acid based 
lipids [stearic acid derived solid lipid (SASL) and oleic acid derived liquid lipid (OALL)], 
and to explore the potential for preparing vancomycin pH-responsive nanostructured lipid 
carriers (VCM-SAOA-NLCs). The synthesis and characterization of the lipids are 
described followed by their use for the preparation and characterization of VCM loaded 
NLCs.  
 
2. Materials and methods  
2.1  Materials 
Stearic acid and serinol were purchased from Sigma-Aldrich (UK), while Trifluoroacetic 
acid (TFA), N, N’-dicyclohexyl carbodiimide (DCC) and di-tert-butyl dicarbonate (t-
Boc) were purchased from Merck (Germany). Triisopropylsilane (TIPS) and tertiary 
butyl acrylate (TBA) were purchased from Sigma-Aldrich (Germany). Mueller Hinton 
Agar (MHA) and Nutrient Broth were obtained from Biolab Inc. (South Africa), and 
Vancomycin hydrochloride, 4-(Dimethylamino)pyridine (DMAP), oleic acid (OA), 
Mueller Hinton broth 2 (MHB), dialysis tubing cellulose membrane and all other reagents 
were procured from Sigma-Aldrich (USA). Vancomycin hydrochloride was converted to 
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the vancomycin free base (VCM), according to a previously reported method [12]. Milli-
Q purified water was obtained from an Elix® water purification system Millipore Corp. 
(USA). Bacterial strains used were Staphylococcus aureus Rosenbach (ATCC®BAA-
1683) (MRSA) and Staphylococcus aureus (ATCC 25922) (SA). 
 
2.2. Synthesis and characterization of the lipids 
 
 
Scheme 1 Synthesis of stearic acid derived solid lipid (SASL).  
2.2.1. di-tert-butyl 3,3'-((1,3-dihydroxypropan-2-yl) azanediyl) dipropionate 1  
Compound 1 was synthesized via Michael’s addition of the amino group of serinol to tert-
Butyl methacrylate (TBA) [212]. Briefly, to a stirred solution of 3.55 g (0.039 mol) of 
serinol in methanol, 15 g (0.117 mol) of TBA was added and refluxed for 12 hours. After 
completing the reaction by TLC, methanol was removed under reduced pressure and the 
crude purified by column chromatography on silica gel (hexane/ethyl acetate, 6:4) to give 
compound 1 as a clear viscous liquid with a high yield of above 87%. Characterization 
data is as follows: IR (ATR): 3315, 1682, 1160 cm-1; 1H NMR (400 MHz, CDCl3): δ 1.37 
(s, 18H), 2.29 – 2.34(t, 4H), 2.79 – 2.82 (m, 5H), 3.48 – 3.58 (m, 4H). 13C NMR (400 
MHz, CDCl3): δ 28.0, 35.0, 45.7, 59.7, 63.0, 80.6, 172.2; HRMS (ES-TOF): [M + H] + 
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calculated for C17H33NO6+H
+: 348.2387, found 348.2393 (Figure S3; Supplementary 
material). 
2.2.2. 2-(bis(3-(tert-butoxy)-3-oxopropyl) amino) propane-1,3-diyl distearate 2 
To the solution of stearic acid (8.5 g, 0.02995 mol) in dry DCM, N, N’-
Dicyclohexylcarbodiimide (7.09 g), DMAP (0.9 g) and compound 1 (5 g, 0.0149 mol) 
were added [213], with the resulting mixture being stirred for 24 hours. DCC urea was 
filtered off, and the filtrate was concentrated and purified by column chromatography on 
silica gel (hexane/EtOAc, 8: 2) to obtain a white solid lipid (compound 2) with yield of 
76.3%. Characterization data are as follows: IR (ATR): 2913, 2849, 1725, 1469, 1392-
1366, 1149 cm-1. 1H NMR (400 MHz, CDCl3): δ 0.792- 0.826 (m, 6H), 1.18 (m, 57H), 
1.37 (m, 18H) 1.51 – 1.55 (m, 4H), 2.21 – 2.25(m, 7H), 2.8 (m, 4H), 4.12 – 4.18 (m, 4H). 
13C NMR (400 MHz, CDCl3): δ14.11, 22.69, 24.89, 28.11, 29.19 – 29.7, 31.92, 34.27, 
36.00, 47.19, 57.7, 62.5, 76.69, 77.01, 77.33, 80.37, 171.6, 173.5; HRMS (ESI m/z) [M 
+ H] + calculated for C53H101NO8+H
+: 880.7606, found 880.7630 (Figure; Supplementary 
material).  
2.2.3. 3,3'-((1,3-bis(stearoyloxy)propan-2-yl)azanediyl)dipropionic acid 3  
For the hydrolysis of tertiary butyl esters of compound 2, a previously reported method 
was adopted with slight modifications [214]. To the solution of compound 2 (7 g) in dry 
DCM, a mixture of TFA and TIPS (as scavenger) in the ratio 9:1 was added at room 
temperature and stirred for six hours.  The excess TFA was removed under reduced 
pressure at room temperature, after which the crude mixture was purified by column 
chromatography (Chloroform/MeOH, 9: 1) to obtain a white solid, with the yield being 
92%. Characterization data are as follows: IR (ATR): 3450, 2915, 2850, 1728, 1462, 
1359, 1182 cm-1; 1H NMR (400 MHz, CDCl3): δ 0.791- 0.825 (m, 6H), 1.18 (m, 57H), 
1.49 – 1.52 ( m, 4H) ,2.25 – 2.28 ( t, 4H), 2.84  (m, 4H), 3.47 ( m, 4H), 3.9 (m, 1H), 4.32 
– 4.48 ( m, 4H);13C NMR (400 MHz, CDCl3): δ 14.10, 22.69, 24.60, 27.93, 28.72 – 29.75, 
31.93, 33.6 – 33.77, 48.36, 58.73, 59.41, 82.6, 173.81,173.05; HRMS (ESI m/z) [M+H]+ 
calculated for C45H85NO8+H
+
 :768.6354; found 768.6348 (Figure S3;Supplementary 
material). 
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Scheme 2 Synthesis of oleic acid derived liquid lipid (OALL).  
 
2.2.4. tert-butyl (1,3-dihydroxypropan-2-yl)carbamate 4  
To a stirred solution of serinol 3 g (0.0329 mol) in methanol, di-tert-butyl dicarbonate 
(9.3 g, 0.043 mol) was added and stirred overnight at room temperature [33]. Methanol 
was removed by evaporation to form a white crystalline compound 4 with a yield of 
95.85%. Characterization data are as follows: IR (ATR): 2923, 1721, 1160 cm-1; 1H NMR 
(400 MHz, CDCl3): δ 1.34 (s, 9H), 3.56 – 3.68(m, 5H), 3.8 (s, 1H), 5.43 (s, 1H); 13C NMR 
(400 MHz, CDCl3): δ 28.3, 53.1, 62.3, 79.87, 156.4; HRMS (ESI m/z) [M + H]+ 
calculated for  C8H17NO4+Na
+: 214.1056; found  214.1055 (Figure S3;Supplementary 
material). 
2.2.5. 2-((tert-butoxycarbonyl)amino)propane-1,3-diyl dioleate 5 
To a solution of oleic acid (6.4 g, 0.022 mol) in dry DCM, DCC (5.1 g, 0.0247 mol), 
DMAP (0.7 g, 0.0057 mol) and compound 4 (2 g , 0.0105 mol) were added and stirred 
for 24 hours [213]. The DCC urea formed was filtered off and the solvent removed under 
reduced pressure. Isolation of the pure product from the reaction mass was done via 
column chromatography on silica gel (hexane/EtOAc, 8: 2) to obtain a yellow viscous 
lipid, with yield of 88.3%. Data from characterization are as follows: IR (ATR): 3345, 
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2850-2975 1724, 1467, 1366,1252, 1149 cm-1; 1H NMR (400 MHz, CDCl3): δ 0.8 – 0.82 
(m, 6H), 1.2 – 1.24 (m, 40H), 1.38 (s, 9H), 1.53 – 1.57 (m, 4H), 1.91 – 1.96 (m, 8H), 2.23 
– 2.27 (m, 4H),  3.99 – 4.14 (m, 4H), 4.73 (m, 1H), 5.26 – 5.29 ( m, 4H); 13C NMR (400 
MHz, CDCl3 ): δ 14.0,  22.6 ,24.8, 27.1, 28.3, 29.0, 29.1, 31.8, 34.0, 53.3, 62.8, 129-130, 
156.4, 173.3; HRMS (ESI m/z) [M + H]+ calculated for C44H81NO6+Na
+: 742.5962; 
found 742.5953 (Figure S3;Supplementary material). 
2.2.6. 2-aminopropane-1,3-diyl dioleate 6 
Compound 5 obtained from the earlier step was dissolved in dry DCM, and a mixture of 
TFA and TIPS in the ratio of 9:1 was added at room temperature and stirred for four hours 
[214]. After completing the reaction, the excess TFA was carefully removed under reduce 
pressure and the crude product purified via column chromatography (silica, mesh size 
60–100) (Chloroform/MeOH, 9: 1) to obtain a yellow brownish viscous oil with a yield 
of 94%. Characterization was as follows: IR (ATR): 2923, 1708, 1672, 1461, 1165, 800, 
722 cm-1; 1H NMR (400 MHz, CDCl3): δ 0.87 – 0.90 (m, 9H), 1.27 – 1.3 (m, 43H), 1.58 
– 1.61 (m, 4H), 1.92 – 1.95 (m, 7H), 2.28 – 2.29 (m, 4H), 4.21 – 4.33 (m, 4H), 5.24 – 
5.32 ( m, 4H); 13C NMR (400 MHz, CDCl3 ) δ 14.0,  20.9, 22.54, 22.6, ,24.8, 25.6, 27.2, 
, 29.0, 29.1, 29.7, 31.9, 33.6, 33.9 , 48.5, 62.8, 127.88, 129.67, 129.96, 130.15, 155 
173.61; HRMS (ESI m/z) [M + H]+ calculated for C39H73NO4+H
+: 620.5634; found 
620.5618 (Figure S3;Supplementary material). 
2.3. In vitro cytotoxicity 
MTT assay was performed to evaluate the biosafety of SASL and OALL  following a 
previously reported method [57, 215]. Human lung epithelial (A549), human embryonic 
kidney (HEK-293) and human liver (HEP G2) cell lines were cultured in a medium 
supplemented with 10% fetal bovine serum and 1% penicillin and streptomycin solution 
and incubated for 24 hours under a humidified atmosphere of 5% CO2 at 37 ℃. 
Thereafter, SASL and OALL samples were dissolved in dimethyl sulfoxide and distilled 
water diluted in the culture medium to give final concentrations of 20, 40, 60, 80 and 100 
μg/ml.  
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Following the exponential growth phase, the cell lines were collected and seeded 
equivalently (2.4 × 103) into a 96-well plate and incubated for 24 hours to allow cell 
adherence. Thereafter, the culture medium was removed and replaced with the fresh 
medium (100 ml per well) containing the test samples. Culture medium with cells only 
was used as a negative control, while culture medium without cells was used as a blank.  
After incubation, the culture medium containing the test samples were removed and 
replaced with fresh culture medium and MTT solution (100 μl each). After four hours of 
incubation, the media and MTT solution were removed and 100 μl of dimethyl sulfoxide 
was added to each well to solubilize the MTT formazan. The absorbance corresponding 
to each well was measured using a microplate spectrophotometer (Spectrostar nano, 
Germany) at 540 nm, with all the experiments being run in six replicates. The following 
equation was used to determine percentage cell viability: 
 
                   % Cell viability = (
A540nm treated cells
A540nm untreated cells 
) × 100         (1) 
 
2.4. Preparation of VCM-SAOA-NLCs 
A previously reported hot homogenization and ultrasonication method were employed to 
prepare the VCM loaded SASL and OALL pH-responsive NLCs (VCM-SAOA-NLCs) 
[216]. Briefly, the lipid phase, consisting of a total of 500 mg of OALL and SASL lipids 
in varying ratios and VCM (20 mg) were mixed and melted at a temperature above the 
melting point of the lipid. Meanwhile, the aqueous phase was prepared by dissolving 250 
mg of Tween 80 in 20 ml distilled water and heated separately to the same temperature. 
Both phases were mixed and homogenized for 15 min at 6000 rpm with an Ultra Turrax 
T-25 homogenizer (IKA Labortechnik, Germany), the resultant emulsion being subjected 
to sonication (30% amplitude) for 10 min and subsequently cooled to 20 ºC using an ice 
bath, with the final volume being made up to 20 ml by adding distilled water. Blank (drug-
free)-SAOA-NLCs was prepared using the same technique, with batches being prepared 
in triplicate. 
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2.5. Size, Polydispersity Index (PDI), Zeta Potential (ZP) and Morphology  
The size, PDI, and ZP of VCM-SAOA-NLCs were measured by dynamic light scattering 
technique using a Zetasizer Nano ZS90 instrument (Malvern Instruments Ltd., UK) at 25 
°C. NLCs sample was appropriately diluted with appropriate phosphate buffer solutions 
(PBS) to obtain concentrations that were within the instrument’s sensitivity range, the 
measurements being performed in triplicate [4, 31, 217]. 
The morphology of VCM-SAOA-NLCs was determined by transmission electron 
microscopy (TEM). The samples diluted and negatively stained with 1% uranyl acetate 
(UA) solution, then samples mixed with UA were deposited on a copper grid and air-
dried before visualizing using a transmission electron microscope (JOEL JEM-1010, 
Japan) operated at an accelerating voltage of 100 kV [217]. 
 
2.6. Entrapment efficiency (EE) and drug loading (DL) 
The EE and DL of VCM-SAOA-NLCs were determined by an ultrafiltration method. 
Briefly, NLCs suspension (3 ml ) was placed in Amicon® Ultra-4 centrifugal filter tubes 
(Millipore Corp., USA) of 10 kDa pore size and centrifuged at 2000 rpm at 25 °C for 45 
min [12]. The amount of the unentrapped VCM in the filtrate was detected using a 
validated High-Pressure Liquid Chromatography (HPLC) (Shimadzu, Japan) method, 
with UV detection at a wavelength of 280 nm. The mobile phase consisting of a mixture 
of water with 0.1 % TFA and acetonitrile (85/15 v/v), which was pumped through 
Nucleosil 100-5C18 column (150 mm X 4.6 mm internal diameter) at a flow rate of 1 
ml/min. with an injection volume of 100 μl. The regression equation and linearity (r2) 
were y = 32376 x − 149,208 and 0.9915 respectively. The EE (%) and DL (%) were 
calculated using the following equations [56, 193, 218, 219]. 
 
                         EE (%) = (
Weight of VCM in NLCs
Weight of VCM added
) × 100                 (2) 
                         DL (%)  = (
Weight of VCM in NLCs
Total weight of nanoparticles
) × 100        (3) 
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2.7. Thermal profiles  
The thermal profiles of the VCM, SASL, physical mixture and lyophilized drug loaded 
NLCs were determined by differential scanning calorimetry (DSC) using a DSC-60 
differential scanning calorimeter (Shimadzu, Japan). Briefly, appropriate quantities of the 
samples were placed in aluminum pans and sealed with lids. The scanning was performed 
in a temperature range of 30 °C to 300 °C at a rate of 10 °C/min with nitrogen flow rate 
of 10 ml/min, with an empty pan being used as a reference [156]. 
2.8. In vitro drug release 
The in vitro release studies were carried out using a dialysis bag technique to investigate 
the release behavior of drug loaded pH-responsive NLCs and blank-SAOA-NLCs. 
Dialysis bags (pore size: 8000–14,400 Da) containing 2 ml of the drug-loaded NLCs and 
its respective blank were placed in 40 ml PBS solutions of pH 6 and 7.4 at 37 °C in a 
shaking incubator and stirred at 100 rpm. 
At predetermined time intervals, 3 ml of the samples were withdrawn and replaced with 
equivalent quantities of the fresh PBS solutions of pH 6 and 7.4 to maintain a constant 
volume. The amount of VCM released at each time interval was determined by HPLC 
(Shimadzu, Japan) with UV detection at a wavelength of 280 nm, as described above. 
The regression equation and linearity (r2) were y = 32376 x - 149,208 and 0.9915 
respectively, with each experiment being performed in triplicate [56, 156, 219, 220]. 
2.9. In vitro drug release kinetics and mechanism 
Drug release kinetics of VCM-SAOA-NLCs were investigated using various 
mathematical models, including zero order, first order, Higuchi, Weibull, Hixson-
Crowell, and Korsmeyer–Peppas. The correlation coefficient (R2) and root mean square 
error (RMSE) were calculated to obtain the best fit model. Moreover, the Korsmeyer–
Peppas model release exponent (n) was calculated to determine the release mechanism. 
These in vitro drug release kinetics parameters were calculated using DDSolver software 
[219, 221]. 
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2.10. Molecular Modelling 
Molecular modeling was undertaken to understand the interactions that occurred between 
the VCM and lipids carriers (SASL and OALL), as well as the effect of lipid ratio on the 
EE of VCM in the presence of a constant ratio of Tween 80 as a stabilizer [23]. All 
molecular modeling techniques were performed using Biovia Materials Studio (MS) 2016 
that was installed on the remote server at the Centre for High-Performance Computing 
(CHPC) (Cape Town South Africa). The structure of VCM (PDB:1SHO) was obtained 
from RCSB website, SASL and OALL were drawn using ChemBioDraw Ultra 14, and 
the Tween 80 structure was obtained from PubChem website (CID 443315), after which 
all the structures were cleaned and the hydrogen atoms were added. 
The smart minimizer algorithm in the geometry optimization option available in the 
forcite module of MS software was used to optimize all the structures to their lowest 
energy conformations. COMPASS force field was applied and the convergence tolerance 
criteria were set to 0.001 kcal/mol during the geometrical optimization study. The 
molecular dynamics (MD) study was performed in a vacuum to obtain a stable complex 
of VCM-SAOA-NLCs. All VCM, SASL, OALL and Tween 80 structures were initially 
placed inside the cubic cell (10 x 10 x 10 nm), with the crystal builder and amorphous 
cell module of MS 2016 being used to construct this model. Geometry optimization of 
the whole system was performed prior to MD simulation using the same protocol as 
mentioned above, and optimization of the cell parameters was allowed during energy 
minimization. The stabilized system was then subjected to MD simulation under periodic 
boundary conditions, which was performed at room temperature over 50 ps. In order to 
understand the effect of the lipid ratio on EE all the MD, studies were conducted in two 
different ratios of 2:1 and 1:1 for SASL and OALL, respectively. The final complex 
structures were then studied for the intermolecular interactions to understand the various 
non-covalent forces that were responsible for the complex formation. Biovia Discovery 
Studio Visualizer was used to depict the interactions in the drug-lipid complex.  
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2.11. In vitro antibacterial activity 
The minimum inhibitory concentration (MIC) values for bare VCM, VCM-SAOA-NLCs 
and the blank (drug-free)-SAOA-NLCs were determined against SA and MRSA at pH 6 
and 7.4 using a broth dilution method. Bacterial cultures were grown overnight in Nutrient 
Broth at 37°C for 18 hours in a shaking incubator (Labcon, USA) at 100 rpm. The 
bacterial cultures were diluted with sterile distilled water to achieve a concentration 
equivalent to 0.5 McFarland’s Standard using a DEN-1B McFarland densitometer 
(Latvia). This was further diluted to 1:150 with sterile distilled water to achieve a final 
concentration of 2 × 105 colony forming units (CFU)/ml. Serial dilutions of bare VCM, 
VCM-SAOA-NLCs, and blank-SAOA-NLCs were prepared in MHB (pH 6 and 7.4), 
inoculated with the diluted bacterial cultures and incubated at 37°C in the shaking 
incubator at 100 rpm for 18 hours. After incubation, the test samples (10 µl) were spotted 
onto MHA and incubated at 37°C for 18 hours, this process was repeated every day for 
five days, with the studies being performed in triplicate. The blank formulation of NLCs 
was used as a negative control while the bare VCM was used as a positive control [57, 
222, 223]. 
2.12. Bacterial cell viability assay 
Cell viability studies on the MRSA cells were performed following a flow cytometry 
assay method. A pure culture of MRSA was grown overnight in Nutrient Broth at 37°C 
in a shaking incubator (Labcon, USA)  at 100 rpm. Thereafter, the bacteria were diluted 
with sterile deionized water to achieve a concentration equivalent to 0.5 McFarland 
standard using a DEN-1B McFarland densitometer (Latvia). The bacterial suspension was 
further diluted to 1:150 with sterile deionized water to obtain a final concentration of 5 × 
105 colony forming units (CFU)/ml. Thereafter, 15 μl of the bacterial suspension was 
added to a 96 well plate containing 135 μl of pure VCM (positive control), and VCM-
SAOA-NLCs at the MIC concentrations (7.8 μg/ml and 0.98 μg/ml respectively), and 
incubated at 37 °C in a shaking incubator (100 rpm). The untreated MRSA cells were 
used as a negative control. The percentage cell viability being determined after six hours 
of incubation [224]. VCM and VCM-SAOA-NLCs broths  (50 μl) were added to flow 
cytometry tubes each containing 350 μl of the sheath fluid and vortexed for 5 min. The 
mixture was incubated for 30 min with 5 μl of a non-cell wall permeant propidium iodide 
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(PI) fluorescent nucleic acid dye that binds to DNA by intercalating between the bases. 
PI has an excitation and emission spectrum spectra of 488/636 nm, and once DNA binds, 
its fluorescence is enhanced 20- to 30-fold to the blue wavelength [225-227]. The BD 
FACSCANTO II (USA) instrument was used for flow cytometry, with its settings 
including a sheath fluid flow rate of 16 ml/min and a sample flow rate of 0.1 ml/min. Data 
with the fixed cells were collected using a flow cytometer software (BD FACSDIVA 
V8.0.1 software [USA]), after which the captured data were analyzed using Kaluza-1.5.20 
(Beckman Coulter USA) flow cytometer software. The voltage settings used for 
fluorescence-activated cell sorting (FACS) analysis were: 731 (forward scatter [FSC]), 
538 (side scatter [SSC]), 424 (Fluorescein isothiocyanate [FITC]) and 444 for PI. Bacteria 
were initially gated using forward scatter. Subsequently, cells of the appropriate size were 
then gated with at least 10,000 cells being collected for each sample in triplicate, then the 
position of the ‘live’ and ‘dead’ cells gates was determined. To avoid background signal 
from particles smaller than bacteria, the detection threshold was set to 1,000 in SSC 
analyses [228].  
 
2.13. In vivo antibacterial activity and histological evaluation 
For further evaluation of the anti-MRSA activity of the optimal VCM-SAOA-NLCs 
formulation, a mouse skin infection model was used for in vivo antibacterial activity 
assessment, as per the protocol described in other papers [31, 45, 57]. BALB/c mice 
weighing 18-20 g were obtained from the University of KwaZulu-Natal’s Biomedical 
Research Unit. A day before the experiment, the back hair of the mice was shaved off and 
the mice skin was disinfected with 70% ethanol. The next day, the mice were divided into 
three groups of four mice each: positive control, treatment, and negative control. Then, 
50 µl of MRSA was diluted in saline solution to achieve a concentration of 1.5 x 108 
CFU/ml and administered intradermally. Thirty minutes later the positive control group 
and treatment group were injected at the same infected sites of the mice with bare VCM 
and VCM-SAOA-NLCs respectively, while the negative control group was injected with 
the MRSA only. The mice were kept under observation for 48 hours under the normal 
condition of 12 hours light and 12 hours darkness at 19–23℃, 55 ± 10 % relative humidity 
with adequate ventilation. Thereafter, the mice were sacrificed and the infected skin was 
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harvested and homogenized in 5 ml of PBS (pH 7.4). The tissue homogenates were 
serially diluted with PBS (pH 7.4), after which 20 µl were spotted onto on nutrient agar 
plates and incubated at 37 °C for 24 hours and the CFU was determined [4, 229].  
Histological evaluations were conducted on the excised skin from the injection site, with 
the skin samples being transferred directly after harvesting and excision from normal 
saline into 10% buffered formalin. After seven days, the skin samples were embedded in 
paraffin wax after dehydration in an ethanol gradient. The tissue wax blocks were 
sectioned using a microtome (Leica RM2235, Leica Biosystems, Germany), and sections 
were collected on slides, dried and stained with hematoxylin and eosin (H&E). The 
sections were examined and captured with a Leica Microscope DM 500 that was fitted 
with a Leica ICC50 HD camera (Leica Biosystems, Germany) [57]. All the animal 
experiments were performed in accordance with the protocol approved by the Animal 
Research Ethics Committee of the University of KwaZulu-Natal (Approval number. 
AREC/104/015PD).   
 
2.14. Statistical analysis 
Statistical analysis of the data was performed using one-way analysis of variance 
(ANOVA) followed by Bonferroni’s multiple comparison tests using GraphPad Prism® 
6 (GraphPad Software Inc., USA). Individual groups were compared against each other 
and the difference considered significant when the P value was < 0.05, with the results 
being expressed as a mean ± standard deviation (SD).  
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3. Results and discussion 
3.1. Synthesis and characterization of the lipids 
The solid lipid SASL was synthesized in three steps. The first step involved the bis-aza-
Michael addition of tertiary butyl acrylate to serinol to form compound 1 which was 
confirmed by both 1H NMR and 13C NMR. The appearance of a strong multiplet at δ 1.37 
ppm integrating for 18 protons in 1H NMR, and the appearance of carbon peaks at δ 28, 
35, 80 and 172 in 13C NMR, representing isobutane carbons, -CH2C=O-, C(CH3)3-COO 
- and C=O, confirmed the formation of compound 1. Secondly, the two free hydroxyl 
groups on compound 1 were coupled with stearic acid using DCC/DMAP chemistry to 
obtain compound 2. The product was confirmed by the appearance of aliphatic peaks at 
δ 0.808 (multiplet), δ 1.18 (multiplet) and δ 1.53 (multiplet) on 1H NMR. Lastly, tertiary 
butyl esters of compound 2 were hydrolyzed to form SASL, using TFA and TIIPS as 
scavengers to avoid any possible side reactions. The successful synthesis of SASL was 
confirmed by the disappearance of isobutane peaks at 1.4 ppm in 1H NMR and at 28 ppm 
in 13C NMR.  
For the OALL synthesis, firstly, the amine group on serinol was protected using di-ter-
butyl dicarbonate (t-Boc) and the product confirmed by both 1H NMR and 13C NMR.  A 
peak appeared at δ 1.34 ppm in 1H NMR, which integrated to 9 protons, while the peak 
at δ 28.3 ppm in 13C NMR confirmed the isobutane chain. In addition, a peak at δ 156. 4 
ppm confirmed the presence of carbonyl group of boc amide which confirmed the t-Boc 
protection of an amino group of serinol (compound 4). Compound 4 was coupled with 
oleic acid using DCC and DMAP as catalysts to yield compound 5. In 1H NMR, the 
characteristic peaks at δ 0.803 to 0.837 ppm and peaks at δ 5.28 to 5.299 represented 
terminal -CH3, and olefinic protons of oleic acid respectively, confirming the synthesis of 
compound 5, these peaks integrating to their expected theoretical calculated protons 
(supplementary material). Compound 5 was subjected to Boc deprotection using TFA and 
TIIPS to obtain compound 6 as OALL. The disappearance of isobutane peaks at δ 1.4 
ppm in 1H NMR and at δ 28 ppm in 13C NMR indicated the successful cleavage of boc 
deprotection and confirmed the successful synthesis of OALL.   
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3.2. In vitro cytotoxicity 
A cytotoxicity study was performed in order to determine the biosafety of the newly 
synthesized lipids. The MTT results revealed that the synthesized novel lipids SASL and 
OALL displayed a high percentage (> 75%) cell viability after 48-hour exposure across 
the concentration range studied (Fig. 1). SASL and OALL displayed a cell viability 
between 77.55 to 94.83 % and 75.70 to 87.20 % respectively (Fig. 1 A and B 
respectively). Although the % cell viability decreased slightly at the higher 
concentrations, there were no clear dose-dependent trends observed for either SASL or 
OALL across all the cell lines studied (Fig. 1). Studies report that cell viabilities greater 
than 75% are considered as low toxicity in the framework of safety use [57, 230]. SASL 
and OALL can, therefore, be considered to be biologically safe and nontoxic to 
mammalian cells.   
 
Fig. 1. Cytotoxicity evaluation of various concentrations of A) SASL B) OALL against 
A 549, HEK-293, and HEP G2 cells. 
3.3. Preparation of drug loaded NLCs 
Having confirmed the structure of SASL and OALL and their biosafety, their potential 
for NLCs formation was then explored. VCM-SAOA-NLCs were prepared from the 
newly synthesized lipids using OALL as liquid lipid and SASL as a solid lipid, a Tween 
80 surfactant, and VCM by hot homogenization followed by ultrasonication. Preliminary 
studies were performed using different ratios of lipids to obtain a formulation with 
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optimal size, PDI and acceptable switch from negative to the positive charge in different 
pH with maximum entrapment efficiency of the VCM (Table 1). 
Table 1 Particle size, PDI, and ZP of VCM-SAOA-NLCs 
SASL: 
OALL 
ratio 
pH Particle size 
(nm) 
PDI ZP (mV) EE% 
 7.4 555.7 ± 76.3 0.70 ± 0.27 -4.7± 0.7  
0.5:1 6.0 798.6 ± 318 0.72 ± 0.28 -2.8 ± 0.9 57.23± 3.0 
 4.5 854,7 ± 125 0.75 ± 0.20 11.0 ± 1.3  
 7.4 290.3 ± 20 0.36 ± 0.08 -7. 4 ± 1.3  
1:1 6.0 358.3 ± 38 0.49 ± 0.06 0.2 ± 0.3 69.25±2 
 4.5 442.8 ± 80 0.49 ± 0.40 12.1 ± 0.4  
 7.4 225.2 ± 9.1 0.258 ± 0.02 -9.2 ± 2.7   
2:1 6.0 322.4 ± 37.7 0.386 ± 0.02 3.37 ± 0.8 88.7±13.12 
 4.5 458.7 ± 6 0.431 ± 0.04 9.8 ± 0.4  
 
At pH 7.4, as the solid lipid: liquid lipid ratio increased from 0.5:1 to 2:1, the particle size 
and PDI of the NLCs decreased from 555.7 nm to 225.2 nm and 0.7 to 0.2 respectively, 
whereas the ZP values shifted from -4.7 mV to -9.2 mV, while the EE percentage 
improved from 57% to 88%. The increase in particle size, in accordance with an increase 
in liquid lipid content, may have led to an increase in the viscosity and consequently 
NLCs swelling [231, 232].  
Alternatively, the higher solid lipid to liquid lipid ratios formed more stable nanoparticles 
with homogeneous size distributions and enhanced EE. The size, PDI, ZP, and EE of 
VCM-SAOA-NLCs formulations were similar to other reported NLCs using fatty acids 
lipids [147, 233, 234] and confirmed the ability of the newly synthesized lipids to form 
VCM loaded NLCs.  
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The VCM-SAOA-NLCs formulation with a solid lipid: liquid lipid ratio of 2:1 
specifically displayed a size, PDI and ZP of 225.2 ± 9.1 nm, 0.258 ± 0.02, -9.2 ± 2.7 mV 
respectively. The EE (%) and DL (%) for this VCM-SAOA-NLCs were found to be 88.7 
± 13.12 % and 3.55 ± 0.52 % respectively. This enhanced EE (%), compared to the NLCs 
with lower solid lipid, could be due to the higher partitioning of the VCM free base in the 
lipid matrix, due to its hydrophobic nature. In addition, SASL has two carboxylic arms, 
which increase the ion pairing between the solid lipid and VCM, leading to higher 
entrapment. Similar results were reported where ion-pairing mechanism enhanced the EE 
(%) of poorly soluble drugs in solid lipid nanoparticles [12, 235, 236] and polymeric 
nanoparticles [237]. Thus, the VCM-SAOA-NLCs system consisting of a solid lipid: 
liquid lipid ratio of 2:1 was considered the optimal formulation, as it had the lowest size, 
smallest PDI and highest stability with highest EE (%), and was characterized further. 
  
3.4. Characterization of the optimal VCM-SAOA-NLCs  
To obtain more information about the VCM-SAOA-NLCs size and morphology, a TEM 
investigation was performed. The TEM study demonstrated that VCM-SAOA-NLCs had 
a well-defined spherical shape with an average size of 235.6 nm, which correlated well 
with the results of the dynamic light scattering technique (Fig. 2), these results being 
comparable to other NLCs reported [127, 238]. 
To determine the pH responsiveness of the VCM-SAOA-NLCs, they were dispersed in 
buffer solutions with different pH ranges (7.4, 6 and 4.5). The optimal formulation, as 
shown in Table 1, shows pH responsiveness in terms of size, PDI, and ZP. At pH 7.4, 6 
and 4.5, the VCM-SAOA-NLCs size increased from 225.2 nm to 322.4 nm and 458.7 nm 
respectively, the PDI increased from 0.258 to 0.386 and 0.431 respectively, and the ZP 
also switched from -9.2 ± 2.7 mV to +3.37 mV and +9.8 mV respectively. 
In the VCM-SAOA-NLCs, the primary amine group of OALL binds to the carboxylic 
acid group of SALL by proton exchange ionic interaction [239]. At pH 7.4, the NLCs are 
negatively charged due to the carboxylate ions of the SASL on the NLCs surface. At low 
pH, due to the high concentration of H+ ions, both the amine group of OALL and the 
carboxylate group of SASL remain protonated, which results in a breakage of the ionic 
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interaction between the two lipids [240-242], this phenomenon was demonstrated by the 
positive ZP at low pH. The breakage of the ion pair bridge between the two lipids 
minimizes their affinity to each other, causing disassembly of the NLCs-dispersion and 
an eventual increase in their hydrodynamic diameter. The above change in size signifies 
a change in the conformational structure of the NLCs, while the switch from negative to 
a positive charge is expected to have an influence on increasing drug release and 
promoting interactions with the negatively charged bacterial cell wall for enhancing 
antibacterial activity [28, 31, 45, 243]. 
 
 
Fig. 2. Morphology of VCM-SAOA-NLCs.  
 
3.5. Thermal profiles 
The purpose of DSC study was to confirm the entrapment of VCM in the NLCs through 
investigating the crystallization state and change of thermal behavior of the NLCs 
components. The thermal profiles of SASL, VCM, lyophilized VCM-SAOA-NLCs and 
the physical mixture of VCM and SASL were compared (Fig. 3). The endothermic peaks 
of SASL and VCM were observed at 71.53ºC and 103.40ºC respectively, with the 
physical mixture showing nearly the same thermal behavior as the individual components. 
While the peak for the lyophilized VCM-SASL-NLCs appeared at 62.57ºC, the VCM 
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peak disappeared, which could be attributed to its transformation from the crystalline 
form into the amorphous form, as it was entrapped within the NLCs matrix [66]. 
 
Fig. 3. DSC thermogram of (A) SASL (B) VCM (C) physical mixture of VCM and 
SASL and (D) lyophilized VCM-SAOA-NLCs.  
 
3.6. In vitro release profile 
The in vitro release profile of the bare VCM and VCM-SAOA-NLCs were investigated 
using the dialysis bag diffusion technique at pH 7.4 and pH 6. At pH 7.4, the bare VCM 
release was almost complete within the first 24 hours, while VCM-SAOA-NLCs released 
only 47 % at the same time point (Fig. 4). In comparison with bare VCM, the VCM-
SAOA-NLCs release was slower, indicating sustained release profiles. This prolonged-
release could be attributed to the lipid matrix of the VCM-SAOA-NLCs, which retain the 
hydrophobic VCM free base for a longer time [12]. In addition, fatty acids long carbon 
chain length slows the diffusion rate of the drug, resulting in slower drug release [22, 147, 
154], which could be beneficial for prolonged and sustained antibacterial activity [12, 48, 
244]. 
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Fig. 4.  In vitro drug release profiles of bare VCM and VCM-SAOA-NLCs at pH 7.4 
(n= 3).  
Whilst the VCM-SAOA-NLCs release was similar up to the 4th hour at both pH conditions 
(Fig. 5) thereafter, it had a statistically significant (P < 0.05) faster release at pH 6 
compared to pH 7.4 up to 48 hours. This higher release at lower pH was attributed to the 
protonation of OALL and SASL at acidic media, leading to a breakage of the ion pair 
between the two lipids and the nanoparticles hydrodynamic diameter increasing due to 
electrostatic repulsion between the lipids. This resulted in the NLCs swelling and 
breaking and subsequently leading to higher and faster drug release. This pH-sensitive 
release behavior is significant for enhanced VCM protection at physiologic pH, improved 
targeted release, enhanced localization, and bioavailability at acidic infection sites, thus 
improving the antibacterial activity [28, 31, 45]. 
 
Fig. 5. Effect of pH on drug release profiles of VCM-SAOA-NLCs (n= 3). 
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3.7. In vitro drug release kinetics 
The release data for kinetic analysis of the optimized VCM-SAOA-NLCs was fitted into 
zero order, first order, Higuchi, Weibull, Hixson-Crowell, and Korsmeyer–Peppas 
models (Table 2). Although the VCM-SAOA-NLCs release was higher at pH 6, it had 
similar kinetic behavior to the release at pH 7.4. The highest R2 values were 0.94 and 
0.961, while the lowest root means square error (RMSE) values were 3.04 and 2.89 at pH 
7.4 and pH 6 respectively. Thus, the Weibull model was considered the best fit model for 
the VCM-SAOA-NLCs release at both pH conditions. The Weibull exponent parameter 
(β) value is used to interpret the drug release mechanism, with β ≤ 0.75 indicating a 
Fickian diffusion, and 0.75 < β < 1 indicating a combined mechanism, whereas a β value 
higher than 1 is associated with the complex release mechanism. The values of exponent 
parameter (β) for VCM-SAOA-NLCs were 0.37 and 0.418 at pH 7.4 and pH 6 
respectively, indicating Fickian diffusion as the release mechanism. These results were 
consistent with the (n) values of Korsmeyer-Peppas model, whereas (n) values at pH 7.4 
and pH 6 and were 0.289 and 0.308 respectively, confirming the Fickian mechanism of 
VCM release from the VCM-SAOA-NLCs, as (n) the value was less than 0.5 [219, 221, 
245, 246].  
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Table 2  Release kinetics data from different models.  
Model Equation R2 RMSE Release 
exponent (n) 
pH 6 pH 7.4 pH 6 pH 7.4 pH 6 pH 7.4 
Zero Order Q = k. t + Q0 1.460 -1.783 22.218 20.075   
First Order Q = Q0 . e
kt -0.018 -0.600 14.185 15.219   
Higuchi Q = k. t ½ 0.625 0.495 8.667 8.542   
Korsmeyer-
Peppas 
Q = k . tn 0.936 0.913 3.601 3.531 0.308 0.289 
Hixson-Crowell Q⅓ = kt + Q0
⅓ -0.377 -1.003 16.517 17.025   
Weibull Q = 1 exp [-(t)a/b] 0.961 0.935 2.801 3.043   
R2 = linear regression coefficient, RMSE = Root mean square error 
 
3.8. Molecular Modeling 
Molecular modeling was used to investigate the interaction of VCM with the SAOA-
NLCs system, and the effect of the solid and liquid lipid ratio on drug entrapment 
efficiency. The initial energy of VCM free base, SASL, OALL and Tween 80 were found 
to be 1509.249, 590.150, 354.144 and 213.780 kcal/mol, respectively. Geometry 
optimization using the smart minimizer algorithm in the forcite module led to producing 
more stable molecules, with final energies of 123.318, -164.488, -47.506, and -1.317 
kcal/mol for VCM, SASL, OALL and Tween 80, respectively. The molecular dynamics 
(MD) study for the 2:1 lipid ratio revealed the formation of VCM-SAOA-NLCs. The 
potential energy (mass of the complex) increased from 866.075 kcal/mol to 1367.44 
kcal/mol by the end of MD study (Fig. 6 A), this energy increase confirming the 
successful formation of the VCM-SAOA-NLCs system, as a phase transformation of the 
individual components of the NLCs occurred and produced one stable NLC system [247]. 
When the ratio of the solid lipid to liquid lipid was 1:1, the potential energy was found to 
be 1603.991 kcal/mol by the end of the MD study, and the VCM was observed to interact 
with Tween 80 rather than the SASL or OALL (Fig. 6 B). The lower potential energy at 
a 2:1 ratio (1367.44 kcal/mol) indicated better stability of the system. Furthermore, the 
VCM was incorporated into the SASL (Fig. 6 A) rather than being repelled out, as in the 
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case of 1:1 ratio. This observation may explain the higher EE of VCM at solid lipid: liquid 
lipid of 2:1 compared to the lower EE when the solid lipid: liquid lipid ratio was 1:1 
(Table 1), and can be explained by the competition between the liquid lipid and the VCM 
to interact with the solid lipid. Increasing the amount of solid lipid led to the higher 
partitioning of the VCM free base in the lipid, as the SASL has two carboxylic arms, 
which increases the ion pairing between the solid lipid and VCM, subsequently improving 
the EE [12]. These studies, therefore, confirmed the stability of the NLCs system and 
identified the mechanism behind the higher EE with a higher ratio of the solid lipid 
(SASL) than the liquid lipid (OALL). 
 
 
Fig. 6. The multivalent binding phenomenon of SASL, OALL and Tween 80 with 
VCM. (A) Solid lipid: liquid lipid is 2:1 (B) Solid lipid: liquid lipid is 1:1 
 
3.9. In vitro antibacterial activity 
The in vitro antibacterial activities of bare VCM, VCM-SAOA-NLCs and the blank-
SAOA-NLCs were investigated against SA and MRSA at pH 6 and 7.4 using a broth 
dilution method (Table 3). The MIC value of bare VCM against SA was 3.9 µg/ml at both 
pH conditions and increased to 7.8 µg/ml against MRSA at both pH conditions. MIC 
values of VCM-SAOA-NLCs against SA were 1.95 µg/ml and 0.488 µg/ml, whereas the 
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MIC values of VCM-SAOA-NLCs against MRSA were 1.95 µg/ml and 0.98 µg/ml at pH 
7.4 and pH 6 respectively. These results showed that the VCM-SAOA-NLCs had lower 
MIC values and thus superior antibacterial activity compared to the bare VCM against 
both bacterial strains at both pH conditions. Furthermore, the VCM-SAOA-NLCs 
formulation activity was extended up to 96 hours, while the bare VCM had an activity for 
only 48 hours.  
The enhanced extended anti-microbial activity, in comparison to the bare VCM, could be 
attributed to the small size with the large surface area as well as the lipophilic nature of 
VCM-SAOA-NLCs, which could enable better penetration and uptake into the bacterial 
cell wall, thus enhancing the VCM activity [4, 57, 199]. In addition, the VCM-SAOA-
NLCs release over a prolonged period of time (Fig. 5) could have contributed to the 
extended activity of up to 96 hours compared to bare VCM [12, 248]. Additionally, the 
antibacterial activity of oleic acid can enhance the VCM-SAOA-NLCs efficacy [12, 249, 
250]. 
Importantly, the VCM-SAOA-NLCs had lower MIC values at pH 6 than at pH 7.4 against 
both bacterial strains. At pH 6, the VCM-SAOA-NLCs activity was four and two times 
better against SA and MRSA respectively than at pH 7.4. The superior antibacterial 
activity of the VCM-SAOA-NLCs at acidic pH compared to pH 7.4 may be due to the 
protonation of the VCM-SAOA-NLCs and ion pair bridge breakage, and hence a higher 
VCM release at the acidic site. In addition, the VCM-SAOA-NLCs surface charge 
switching to positive in acidic media can enhance the binding of the VCM-SAOA-NLCs 
with the anionic bacterial cell wall, and therefore release a higher VCM concentrations at 
the acidic infection site, subsequently increasing its uptake by the bacteria cell wall and 
reducing the total number recovered. Therefore, targeting the acidic bacterial site via pH-
responsive nanoparticles represents a very promising platform to develop delivery 
systems that enhance drug localization at infections site to improve the antibacterial 
activity. This strategy will, therefore, go a long way in reducing the emergence of 
bacterial resistance [28, 31, 45]. 
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Table 3 In vitro antibacterial activity of the formulations at pH 7.4 and pH 6 
 
 
3.10. Bacterial cell viability assay 
Having confirmed the antibacterial activity of VCM-SAOA-NLCs, a flow cytometry 
method was used to quantify the viable MRSA bacteria cells after exposure to bare VCM 
and VCM-SAOA-NLCs , and to investigate the VCM uptake [224, 251]. Following 
incubation of MRSA cells with bare VCM and VCM-SAOA-NLCs medium for six hours, 
live/dead bacterial cells in the population were discriminated by detection of the changes 
in bacterial morphology and the internal complexity using PI fluorescent dye. As PI 
cannot cross the membrane of live cells, it is generally used to detect dead cells in the 
population [226, 252]. 
 
 
 
In vitro antibacterial activity at pH 7.4 
Time (hours) 24 48 72 96 24 48 72 96 
SA (MIC µg/ml) MRSA (MIC µg/ml) 
Bare VCM 3.9 250 NA NA 7.8 NA NA NA 
VCM-SAOA-NLCs 1.95 1.95 1.95 3.9 1.95 1.95 1.95 1.95 
Blank- SAOA-NLCs NA NA NA NA NA NA NA NA 
In vitro antibacterial activity at pH 6 
Time (hours) 24 48 72 96 24 48 72 96 
SA (MIC µg/ml) MRSA (MIC µg/ml) 
Bare VCM 3.9 500 NA NA 7.8 NA NA NA 
VCM-SAOA-NLCs 0.488 0.488 1.95 3.9 0.98 0.98 1.95 7.8 
Blank-SAOA-NLCs NA NA NA NA NA NA NA NA 
NA = No activity. The values are expressed as mean ± SD (n=3) 
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Fig. 7. Dot plots of flow cytometry data of subpopulation phenotypes of MRSA cells 
after treatment A) MRSA cells (negative control), B) MRSA cells treated with bare 
VCM at 0.488 µg/ml,  C) MRSA cells treated with bare VCM at its MIC (7.8 µg/ml) 
and D) MRSA treated VCM-SAOA-NLCs at its respective MIC (0.98 µg/ml).  
The phenotypic changes in MRSA cells before and after treatment with bare VCM and 
VCM-SAOA-NLCs at their respective MICs (7.8 μg/ml and 0.98 μg/ml respectively) 
were investigated by plotting PI fluorescence log versus SSC log. MRSA cells treated 
with bare VCM at lower concentration (0.488 µg/ml) was investigated in order to study 
the effect of  bare VCM on MRSA at a concentration lower than the MICs of both bare 
VCM and VCM-SAOA-NLCs which will help to explain the role of SAOA-NLCs to 
enhance the activity of VCM  (Fig. 7) [226]. 
Live MRSA cells (negative events) are represented in dot plots with the quadrants 1 and 
4 (Q1 and Q4). Dead MRSA cells (positive events) showed fluorescence shifts as 
represented in the quadrants 2 and 3 (Q2 and Q3). These shifts indicating the PI uptake 
and intercalation with the DNA of the dead bacterial cells, confirming the changes in cell 
morphology and complexity as result of VCM bactericidal activity. 
MRSA cells showed two distinct subpopulations after treatment with bare VCM and 
VCM-SAOA-NLCs.  The first population displayed a shift in PI fluorescence with no 
shift in the SSC scale as shown by Q3 (Fig. 7 B, C, and D). For negative control cell, 
there was 0 % of dead cells in Q3 (Fig. 7 A). However, MRSA cells treated with bare 
VCM and VCM-SAOA-NLCs at their respective MICs (7.8 μg/ml and 0.98 μg/ml 
respectively) had 90.49 ± 1.23 % and 89.82 ± 1.83 % of dead cells respectively in Q3 
(Fig. 7 C and D). Interestingly, MRSA cells treated with bare VCM at concentration half 
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of VCM-SAOA-NLCs MIC had a lower percentage of dead cells (27.33 %) as shown in 
Q3 (Fig. 7 B).  
The second population showed a shift in PI fluorescence and a shift on SSC scale (Fig. 8 
B, C, and D – Q2). Cells in quadrant (Q2) represented PI cell penetration and intercalation 
with DNA, therefore, resulting in a shift in fluorescence. Cells treated with bare VCM 
and VCM-SAOA-NLCs at their respective MICs had PI uptake of 7.65 ± 1.49 % and 8.20 
± 0.83% respectively as shown in Q2 (Fig. 7 C and D), while bare VCM at the 
concentration half of VCM-SAOA-NLCs MIC had PI uptake of 0.51 % (Fig. 7 B) 
These results clearly demonstrate that VCM-SAOA-NLCs produced the same killing 
effect and slightly better penetrating capabilities although the concentration was 8-fold 
lower compared to bare VCM MIC. Therefore, VCM-SAOA-NLCs had higher killing 
effects compared to bare VCM .This confirms that VCM-SAOA-NLCs had a greater 
impact on the cell wall in comparison to bare VCM and hence resulted in higher uptake 
of PI leading to the change in the phenotype of cells as shown in Q2 [253]. 
  
3.11. In vivo antibacterial activity 
Having confirmed the in vitro antibacterial activity of the VCM-SAOA-NLCs 
formulation, we then assessed its in vivo efficacy to confirm its performance. The BALB/c 
mouse skin infection models were used to further evaluate the VCM-SAOA-NLCs 
activity against MRSA, its counts being 151600, 30000 and 800 CFU/ml for untreated, 
bare the VCM and VCM-SAOA-NLCs groups respectively. These results further reflect 
the enhanced activity of the VCM-SAOA-NLCs against MRSA compared to the bare 
VCM. 
There was a statistically significant (P < 0.05) reduction in MRSA counts that remained 
in the skin of the mice treated with VCM-SAOA-NLCs and bare VCM compared to the 
untreated group. The bacterial burdens were 189- and 5-fold less in the mice skin treated 
with VCM-SAOA-NLCs and bare VCM respectively than the untreated group. However, 
there was a significant (P < 0.05) 37-fold reduction in the bacterial load treated with 
VCM-SAOA-NLCs than bare VCM (Fig. 8). 
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These results confirmed VCM-SAOA-NLCs superior anti-MRSA activity to the bare 
VCM, which could be attributed to the small nanoparticle size, large surface area and 
hydrophobicity of the NLCs, which enhance the MRSA bacterial membrane binding 
capacity and permeability. Moreover, oleic acid is able to enhance penetration across 
bacteria cell wall in addition to its inherent anti-MRSA activity [12, 249, 254], thereby 
possibly contributing to enhanced activity. 
The NLCs as a nanocarrier can also protect VCM and enhance its delivery in a sustained 
manner, thus ensuring higher concentrations at the site of action [48]. At acidic infection 
sites, the VCM-SAOA-NLCs protonation led to the surface charge switching to positive, 
which can improve binding to the negatively charged MRSA cell wall and enhance VCM 
uptake. Subsequently, increasing VCM binding to the terminal D-Ala-D-Ala residues 
targeted site, resulting in bacterial cell wall synthesis inhibition and MRSA colonization 
reduction [28, 31, 45]. Thus, pH-responsive VCM-SAOA-NLCs can be an effective 
multifunctional delivery system that can be used to improve the efficacy of VCM and 
other antibiotics against resistant bacteria, with the added advantage of reducing the high 
dose-dependent toxicity of antibiotics, thereby improving treatment outcomes and patient 
compliance. 
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Fig. 8. In vivo anti-MRSA activity. Data are presented as mean ± SD (n=3). 
 
To further evaluate the skin integrity and morphological changes, a histological analysis 
was performed on all skin samples. Light microscopy analysis of the H&E stained slides 
showed evidence of inflammation and the formation of an abscess at the infection sites 
of the untreated and bare VCM groups (Fig. 9 A and B respectively). The skin samples 
of these groups presented with swelling of the dermal layer and the presence of white 
blood cells at the inflammation site. However, there were no signs of abscess formation 
and only minimal evidence of tissue inflammation in the skin samples of the VCM-
SAOA-NLCs treated group (Fig. 9 C).  
In the untreated group, a large portion of the tissue at the infection site was infiltrated by 
the bacteria, as evidenced by the degree of the inflammatory response to the infection site 
(Fig. 9 A). This inflammatory response was also seen in the bare VCM treated samples, 
but to a lesser extent, these findings correlating directly with the MRSA counts from the 
infection sites. The untreated group displayed the largest number of recovered bacteria 
and displayed the greatest degree of inflammation and abscess formation. The VCM-
SAOA-NLCs treated group displayed the least signs of inflammation and abscess 
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formation, which correlated with its statistically significant lower bacterial load. 
However, the bare VCM group presented a statistically significantly larger number of 
isolated bacteria than the VCM-SAOA-NLCs treated group, displayed more 
histomorphological signs, suggestions of tissue inflammation and abscess formation. 
These histological assessments further confirm the antimicrobial advantage of the VCM-
SAOA-NLCs. 
 
Fig. 9. Light microscopy images of H&E stained samples of (A) untreated (B) bare 
VCM and (C) VCM-SAOA-NLCs treated skin selections.  
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4. Conclusion 
In this study, novel fatty acid based lipids were synthesized and formulated into pH-
responsive NLCs for enhanced targeted delivery of VCM to the acidic infectious site. 
Negatively charged VCM-SAOA-NLCs with a small size, low PDI and acceptable EE 
from novel lipids were successfully prepared and showed responsiveness in terms of size 
and surface charge switching at acidic pH. Drug release was higher at pH 6 due to the 
protonation of both OALL and SASL components of NLCs, leading to breakage of the 
ion pair between them, and the subsequent swelling of NLCs and a burst drug release. In 
silico studies confirmed that the higher EE of VCM at a solid lipid to liquid lipid ratio of 
2:1 (1603.991 kcal/mol) than 1:1 (1367.44 kcal/mol) is due to the higher affinity of VCM 
with the solid lipid than the liquid lipid. The in vitro antibacterial activity against SA and 
MRSA revealed that NLCs activity was enhanced and prolonged at pH 6 as compared to 
pH 7.4. Furthermore, the in vivo BALB/c mouse skin infection models revealed that there 
was a 37-fold reduction in the MRSA colony forming units load in mice skin treated with 
VCM-SAOA-NLCs compared to that treated with bare VCM. Histological investigations 
further confirmed the antimicrobial efficiency of VCM-SAOA-NLCs, as it showed 
minimal signs of tissue inflammation and abscess formation. Therefore, from the present 
work, it could be concluded that OALL and SASL as lipids show potential for preparing 
pH-responsive VCM loaded NLCs with enhanced activity against SA and MRSA. These 
materials may, therefore, contribute to optimizing lipid-based nanoformulations for 
improving the treatment of patients with bacterial infections.  
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CHAPTER 4 
CONCLUSION 
4.1 Introduction 
Infectious diseases are one of the top ten leading causes of death globally. The discovery of 
antibiotics greatly improved the prevention and control infections, however, limitations of 
conventional antibiotic dosage forms, coupled with their irrational use, have contributed to the 
development of therapy complications and a bacterial resistance crisis. One of the major health 
risks is methicillin-resistant Staphylococcus aureus (MRSA) infection, which has increased 
morbidity and mortality rates globally. Vancomycin (VCM) is considered the last effective resort 
against MRSA bacteria, with the spread of resistance being a growing concern, highlighting the 
need to develop strategies to restore VCM efficiency. Although novel nano drug delivery systems 
have shown improved VCM therapy, however, there is still a need to optimize a nano antibiotic 
carrier to protect and stabilize VCM during systemic circulation, target VCM release and improve 
its bioavailability at the infection site. Therefore, current research advances focus on developing 
pH-responsive nanosystems to improve VCM targeted delivery to the acidic infection site. 
Nanostructured lipid carriers (NLCs) is an efficient nanocarrier for antibiotic delivery and 
enhancing antibacterial activity. However, no study in the literature has reported VCM-loaded 
NLCs yet. Therefore, there is a need for identification of novel pH-responsive lipids for 
development of pH-responsive VCM-loaded NLCs formulation. As per the study aim, the results 
of the Objectives outlined the potential of novel fatty acids based lipids to formulate VCM loaded 
NLCs to enhance its antibacterial efficacy.  
The results of the study objectives are as follows as they relate to the Aim are as follow:  
Objective 1. To synthesize pH-responsive novel fatty acid based lipids [stearic acid derived solid 
lipid (SASL) and oleic acid derived liquid lipid (OALL)].  
Objective 2. To characterize the synthesized SASL and OALL  novel lipids using FT-IR, 1H NMR 
and 13C NMR and cytotoxicity studies.  
Objective 3. To explore the potential of SASL and OALL novel lipids for vancomycin loaded 
pH-responsive nanostructured lipid carriers (VCM-SAOA-NLCs) preparation.  
 
Objective 4. To optimize and characterize VCM-SAOA-NLCs in terms of size, polydispersity 
index (PDI), zeta potential (ZP), pH responsiveness, morphology, entrapment efficiency (EE), in 
vitro drug release, in vitro and in vivo antibacterial activity.  
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Objective 5. To undertake in silico studies in order to understand the interactions between VCM 
and the novel lipids as well as the effect of lipids ratio on entrapment efficiency.  
 
The main conclusions generated from the research data are summarized below: 
• Stearic acid derived solid lipid (SASL) and oleic acid derived liquid lipid (OALL) were 
successfully synthesized. 
• FT-IR, 1H NMR, and 13C NMR analysis confirmed the successful synthesis and structures 
of  SASL and OALL lipids.  
• The cytotoxicity studies performed by MTT assay on mammalian cell lines A549, HEK-
293 and HEP G2 revealed that SASL and OALL were biologically safe lipids.   
• Spherically shaped VCM-SAOA-NLCs were successfully prepared using hot 
homogenization followed by ultrasonication method. The optimal formulation showed 
pH-responsiveness in terms of size, PDI, and ZP. VCM-SAOA-NLCs size increased from 
225.2 nm at pH 7.4 to 322.4 nm at pH 6 and 458.7 nm at pH 4.5 respectively. PDI 
increased from 0.258 at pH 7.4 to 0.386 at pH 6 and 0.431 at pH 4.5 respectively. Also, 
ZP switched from -9.2 ± 2.7 mV at pH 7.4 to +3.37 mV at pH 6 and +9.8 mV at pH 4.5 
respectively. The EE % was found to be 88.7 ± 13.12.  
• In vitro drug release studies showed a controlled and pH-dependent VCM release over a 
period of 48 hours. VCM-SAOA-NLCs had faster drug release at pH 6 compared to pH 
7.4. 
• In vitro antibacterial activity against SA and MRSA confirmed the superiority of VCM-
SAOA-NLCs over bare VCM as VCM-SAOA-NLCs had enhanced and prolonged 
activity against both bacterial strains at pH 6 and pH 7.4. Moreover, VCM-SAOA-NLCs 
activity was four times and two times better against SA and MRSA respectively at pH 6 
than at pH 7.4.  
• In vivo antibacterial activity showed that the MRSA burden in mice treated with VCM-
SAOA-NLCs was reduced by189- and 4-fold compared to untreated and bare VCM 
respectively. Histomorphological studies revealed that the skin of VCM-SAOA-NLCs 
treated group showed the least signs of inflammation and abscess formation, confirming 
the superior activity of VCM-SAOA-NLCs compared to the skin of bare VCM and 
untreated groups.  
• In silico studies confirmed that the higher EE of VCM was at a solid lipid to liquid lipid 
ratio of 2:1 (1603.991 kcal/mol) than 1:1 (1367.44 kcal/mol) due to the higher affinity of 
VCM with the solid lipid than the liquid lipid.  
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The findings of this study, therefore, confirmed the potential of the novel pH-responsive fatty acid 
based lipids for preparation of pH-responsive NLCs for enhancing VCM efficacy .In addition ,
these findings can serve as a basis for future research studies on the synthesis of novel pH-
responsive lipids to develop pH-responsive nanocarriers for targeted drug delivery. 
 
4.2 Significance of the findings in the study 
 
The pH-responsive lipids and NLCs carrier were designed to improve VCM targeted delivery to 
acidic infection sites for enhancing antibacterial activity. The significance of the findings of the 
study are as follows: 
New Pharmaceutical Products 
Novel pH-responsive lipids and VCM loaded NLCs formulation were successfully developed in 
this study, which can stimulate the pharmaceutical industry to develop new pH-responsive 
materials and medicines to improve antibiotics delivery.  
Improved patient therapy and disease treatment 
The in vitro and in vivo studies of the developed pH-responsive nanocarrier showed enhanced 
antibiotic activity and sustained VCM release in acidic medium. This nanosystem has the 
potential to improve bacterial infection therapy by protecting the antibiotic during systemic 
circulation, target the delivery of optimal antibiotic concentration to infection sites, decrease 
healthy sites exposure to the antibiotic and enhance bacterial antibiotic uptake. These benefits can 
result in reducing antibiotic dosing frequency, adverse drug reactions, and toxicity. This can lead 
to improving patient compliance, enhancing antibacterial therapy and combating antimicrobial 
resistance threats. 
Creation of new scientific knowledge 
New knowledge was generated by identifying methods of synthesis and characterization of pH-
responsive lipids, as well as antibiotic NLCs formulation and characterization. This can serve as 
a basis for smart nano delivery systems development and enhance their potential pharmaceutical 
applications.  
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Stimulation of new research 
The findings can provide potential research directions to explore the pH-responsive lipids i.e. 
SASL and OALL, for potential applications in pH-responsive nanosystems formulation for 
various drug classes, such as anticancer and anti-ulcer drugs.  
 
4.3  Recommendations for future studies 
The present study concluded that the synthesis of novel pH-responsive lipids and NLCs 
formulation for VCM targeted delivery can enhance treatment of bacterial infections. The 
following studies are recommended to improve drug targeted delivery via pH-responsive VCM-
NLCs:  
• Other saturated and unsaturated fatty acids can be investigated to analyze the effect of 
lipid type and ratios on pH-responsiveness, drug entrapment, drug release, and 
antibacterial activity.  
• Additional in vitro and in vivo antimicrobial activity screening against other Gram-
positive and Gram-negative bacteria should be done to further assess VCM-SAOA-NLCs 
spectrum of activity.  
• Further in silico modeling and simulation studies are required to better understand 
molecular interactions of VCM-SAOA-NLCs with the SA and MRSA bacteria. 
• In vivo pharmacokinetic studies could be conducted to provide more information 
regarding pH-responsive targeted drug delivery, bioavailability, and bio-distribution 
profiles.  
• A large-scale production method could be established to influence the development and 
optimization of the nano antibiotic formulation by local pharmaceutical industries.  
 
4.4 Conclusion 
 
The findings of this study confirmed the potential of the synthesized novel lipids and pH-
responsive nanoformulation in targeting antibiotic delivery to improve bacterial infection therapy. 
This study has contributed a “smart bullet” as an alternative drug delivery approach to address 
the limitations of conventional antibiotic dosage forms and bacterial resistance.
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